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Escherichia coli, é uma bactéria comensal não patogénica, mas que pode 
desenvolver variantes mais virulentas que podem colonizar outros locais que 
não o sistema gastrointestinal. Esta bactéria é uma das principais 
responsáveis por infeções moderadas e graves no ambiente hospitalar e na 
comunidade, estando envolvida na emergência e disseminação de 
resistência às fluoroquinolonas e cefalosporinas de terceira geração. Estima-
se que nos próximos anos o número de mortes causadas pela resistência, 
mesmo em bactérias comensais, será muito alto, fazendo com que seja 
muito urgente encontrar alternativas para combater as bactérias 
patogénicas. Uma abordagem alternativa ou suplementar aos antibióticos é 
a terapia fágica, que utiliza bacteriófagos (fagos) líticos capazes de infetar 
apenas células procariotas. Vários estudos já mostraram efeitos 
encorajadores ao usar a terapia fágica, no entanto, mutantes resistentes a 
fagos têm sido considerados uma grande preocupação, quando se pretende 
usar este método para inativar bactérias patogénicas. A resistência pode, no 
entanto, ser superada com a combinação de fagos e antibióticos, o que 
impede o crescimento de bactérias resistentes e pode ter melhores 
resultados do que quando estas terapias são usadas separadamente. Neste 
estudo, avaliou-se o efeito do tratamento combinado de fagos e antibióticos 
na inativação de E. coli. Para tal utilizou-se o fago Ec-Bio e uma estirpe 
bioluminescente de E. coli testada. Foi testado o antibiótico ciprofloxacina 
em concentrações letais e subletais adicionadas em diferentes tempos (0, 6, 
12 e 18 h) em combinação com o fago que foi testado a duas multiplicidades 
de infeção (MOI), 1 e 100. Em geral, a eficiência do tratamento não 
aumentou com o aumento da MOI. Quando a ciprofloxacina foi adicionada 
em diferentes tempos (6, 12 e 18 h), a produção de fagos foi semelhante à 
obtida com o fago sozinho, mas superior à observada quando a 
ciprofloxacina foi adicionada ao mesmo tempo do fago (tempo 0). A adição 
do fago na ausência de antibiótico causou uma redução de ~ 2,8 log de E. 
coli, após 12 h de tratamento. Os resultados obtidos com as misturas de 
fagos com ciprofloxacina, nas concentrações subinibitórias (1/5 e 1/10 da 
MIC), não causaram diferenças significativas quando comparados com os 
resultados obtidos apenas com o fago, entretanto, após o mesmo período de 
tempo, à MIC e 2xMIC, a inativação bacteriana foi inferior do que a obtida 
somente com o fago. A combinação de fago e ciprofloxacina à MIC e 2xMIC, 
atingiu a taxa máxima de inativação após 18 e 36 h, respetivamente, altura 
em que já se observava recrescimento de E. coli quando o tratamento foi 
feito apenas com o fago. A E. coli foi mais eficazmente inativada quando o 
antibiótico foi adicionado após o fago. A eficácia do tratamento combinado 
variou com a concentração do antibiótico e o tempo de adição do antibiótico, 
evitando mais eficazmente o recrescimento bacteriano quando o antibiótico 
foi utilizado à MIC e adicionado após 6 h da adição do fago. Neste caso, a 
resistência bacteriana foi menor que a observada quando o fago e 
antibiótico foram usados separadamente (4.0 x 10-7 para o tratamento 
combinado, 3.9 x 10-6 para o antibiótico sozinho e 3.4 x 10-5 para os fagos 
sozinhos). O tratamento combinado com fagos e antibióticos pode ser eficaz 
na redução da densidade bacteriana, mas também para prevenir o 
surgimento de variantes resistentes. No entanto, a concentração do 
antibiótico e o seu tempo de aplicação são fatores essenciais a serem 
considerados no tratamento combinado. 
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abstract 
 
Escherichia coli, a non-pathogenic commensal bacterium, can, however, 
developed more virulent variants that colonize outside the gastrointestinal 
system. This bacterium is one of the main responsible for moderate and 
serious infections in the hospital and community environments, being 
involved in the rapid evolution of fluoroquinolones and third generation 
cephalosporin resistance. It is estimated that in the coming years the number 
of deaths caused by resistant bacteria, including even commensal strains, 
will be very high, leading to an increased need to find alternatives to fight 
against pathogenic bacteria. An alternative or supplementary approach to 
antibiotics is phage therapy, which uses lytic bacteriophages (phages) that 
are able to infect only prokaryotes cells. Several studies have already shown 
encouraging effects when using phage therapy, however, phage-resistant 
mutants have been considered a major concern when this method is 
employed to inactivate pathogenic bacteria. Resistance can be overcome 
with the combination of phages and antibiotics, which prevents the re-growth 
of resistant bacteria and reduce more efficiently bacterial density than when 
used separately. In this study, the effect of combined treatments of phages 
and antibiotics in the inactivation of E. coli was evaluated. For that, it was 
used the phage Ec-Bio and the bioluminescent-transformed strain of E. coli. 
It was tested the antibiotic ciprofloxacin at lethal and sublethal concentrations 
added at different times (0, 6, 12 and 18 h) in combination with the phage to 
inactivate E. coli at two multiplicity of infection (MOI), 1 and 100. In general, 
bacterial inactivation did not increase with the increase of MOI. When the 
ciprofloxacin was added at different times (6, 12 and 18 h), phage production 
was similar to the obtained with phage alone, but higher than that observed 
when ciprofloxacin was added at the same time of the phage. The phage 
alone caused a reduction of ~2.8 log of E. coli after 12 h of treatment. The 
mixtures of phage with ciprofloxacin, at sublethal concentrations (1/5 and 
1/10 of MIC), did not cause significant differences when compared with the 
results obtained just with the phage alone, however, after the same time 
period, at MIC and 2xMIC, the inactivation of E. coli was lower than that 
obtained with phage alone. Otherwise, the combination of phage and 
ciprofloxacin at MIC and 2xMIC, reached the maximum rate of inactivation, 
after 18 and 36 h, respectively, but at these times, re-growth of E. coli was 
observed when the phage was used alone. A higher difference was observed 
between the treatment with the mixture phage and antibiotic at MIC and the 
antibiotic alone than when the antibiotic was used 2xMIC. E. coli was most 
effectively inactivated when the antibiotic was added after the phage. The 
efficacy of the combined treatment varied with the antibiotic concentration 
and the time of antibiotic addition, avoiding bacterial regrowth when the 
antibiotic was used at MIC and added after 6 h of phage addition. In this 
case, bacterial resistance was lower than when phages and antibiotics were 
applied alone (4.0 x 10-7 for the combined treatment, 3.9 x 10-6 for the 
antibiotics alone and 3.4 x 10-5 for the phages alone). The combined 
treatment with phages and antibiotics can be effective in reducing the 
bacterial density, but also to prevent the emergence of resistant variants. 
However, the antibiotic concentration and the time of antibiotic application 
are essential factors to be considered in the combined treatment. 
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Objectives, thesis outline and publications 
 
Objectives 
The objective of this study was to evaluate the potential effect of single and combined use 
of phages and antibiotics in the inactivation of E. coli in order to control infections and to reduce 
the development of bacterial resistance to phages and antibiotics. 
 
Thesis Outline 
This document is divided into three chapters. Chapter 1 includes a literature review, serving 
as a basis for the studies carried out in Chapter 2. This Chapter describes the experimental work 
done in order to test the combination of a phage and an antibiotic, using different concentrations 
of antibiotic and phages (two MOIs), to control the emergence of resistant bacteria. Additionally, 
it was tested the influence of time of addition of ciprofloxacin in the inactivation of E. coli. In 
these assays a bioluminescent E. coli was selected as a model microorganism to monitor real-time 
phage therapy kinetics, through the measurement of bioluminescence. It was also tested the 
emergence of resistances to ciprofloxacin or phages alone and to the combination of phages and 
ciprofloxacin. Chapter 3 includes the references used in the present document. 
 
Publications 
 During the dissertation period, I participated in the experimental work of an ongoing 
project, which results were published in this manuscript:  
New insights on phage efficacy to control Aeromonas salmonicida in aquaculture systems: 
An in vitro preliminary study. 
A copy of this manuscript is presented as Annex 1 of this document. 
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1.1. Antibacterial therapy  
Antibiotic is defined as an agent produced naturally by an organism or prepared 
synthetically, used in the treatment and prevention of bacterial infections (Ahmed et al., 2017; 
Nicolaou and Rigol, 2017). In 1928, Alexander Fleming made accidentally an important discovery 
for humanity, by observing the inhibition of a bacterial culture of Staphylococcus aureus, by the 
action of a fungus, Penicillium genus (Gaynes, 2017). After many years, Ernst Chain, Norman 
Heatley and Howard Florey were able to develop a way to isolate penicillin which has been used 
to treat bacterial infections during the World War II. Penicillin was introduced to clinical use in 
1946 where it made a significant effect on public health (Nicolaou and Rigol 2017). During the 
golden age of discovery, 150 types of antibiotics were developed. Since then, the spread of 
resistance has greatly outpaced the rate of drug development (Lobanovska and Pilla, 2017) 
(Figure 1.1). 
 
 
Figure 1.1: Discovery of antibiotics and emergence of antimicrobial resistance (Das et al., 2017). 
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The antibiotics can be classified based on the cellular components or system they affect, 
such as: interference with cell wall synthesis, inhibition of protein synthesis, interference with 
nucleic acid synthesis, inhibition of a metabolic pathway and disruption of bacterial membrane 
structure (Tenover, 2006; Tortora, Funke and Case, 2010; Li et al., 2015). Also, they can be 
classified into bactericidal (if induce cell death) and bacteriostatic (if only inhibit cell) (Nicolaou 
and Rigol 2017). 
 
1.1.1. Mechanisms of action of antibiotics 
Antibiotics are classified into five major groups (Marinho et al., 2016) based on its 
intracellular target and its mechanism of action (Li et al., 2015) (Figure 1.2): 
a) Cell wall Synthesis inhibition (e.g. β-lactams, such as penicillin and derivatives, 
cephalosporins, carbapenems and glycopeptides). These compounds are more 
effective against infection by Gram positive bacteria. That kind of antibiotics have 
the peptidoglycan present on the cell wall as target. The successful treatment 
with these drugs can result in changes to cell shape and size, induce cellular stress 
responses and culminate in cell lysis (Tenover, 2006; Kohanski et al., 2010; Liet al., 
2015). 
 
b) Cell membrane disruption (e.g. the family of polycationic peptide antibiotics, 
such as polymyxins). Drugs that interfere with the cytoplasmic membrane are 
bactericidal. Some antimicrobial agents bind to cellular envelope components, 
such as phospholipids and liposaccharides (LPS), leading to membrane rupture 
and loss of cellular contents, killing the bacterium. (American Society for 
Microbiology, 2005; Mendes and Burdmann, 2010; Li et al., 2015). 
 
c) Nucleic acid synthesis inhibition (e.g. quinolones and rifampicin). This is caused 
by two classes of drugs, fluoroquinolones and rifampicin. The first one interfere 
with DNA synthesis by blocking the enzyme DNA gyrase and the second binds to 
DNA-dependent RNA polymerase, which blocks the synthesis of RNA (American 
Society for Microbiology, 2005; Li et al., 2015).  
 
d) Protein synthesis inhibition (e.g. tetracycline, aminoglycosides, chloramphenicol 
and macrolides). The procedure of mRNA translation involves the ribosome, 
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allowing protein synthesis, and is composed of two subunits, the 50S and 30S. 
Drugs that inhibit protein synthesis bind to ribosomal subunits and are divided 
according to these subunits, interfering with a phase of the protein synthesis 
(Kohanski et al., 2010; Li et al., 2015). 
 
e) Metabolic process inhibition (e.g. sulfonamides and trimethoprim). Antimicrobial 
agents inhibit cytoplasmic enzymes involved in the biosynthesis of essential 
bacterial metabolites, like para-aminobenzoic acid (PABA). PABA is involved in the 
synthesis of folic acid, precursor to the synthesis of nucleic acids. Antibiotics with 
this mechanism can compete with PABA or act on the folic acid synthesis 
pathway, inhibiting the enzyme dihyrofolate reductase (American Society for 
Microbiology, 2005; Rosenthal and Tan, 2011). 
 
 
 
Figure 1.2: Basic sites of antibiotic activity (Murray et al., 2016). 
  
1.1.2. Fluoroquinolones 
Fluoroquinolones are synthetic and one of the most broadly used classes of antibiotics. 
They are bactericidal and inhibit the bacterial enzyme DNA gyrase (topoisomerase type II) or 
topoisomerase type IV, which are essential for DNA replication, recombination and repair. The 
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topoisomerase type II helps to roll up and unroll DNA throughout DNA replication. The enzyme 
binds to DNA and introduces double stranded breaks that let the DNA to unroll. These 
antimicrobial agents bind to the DNA gyrase-DNA complex and permit the fragmented DNA 
strands to be released into the cell, which results in cell death (Mohr, 2016; Murray et al., 2016). 
Ciprofloxacin (Figure 1.3) is a second-generation fluoroquinolone (Scoper, 2008) and has a 
bactericidal activity (Mohr, 2016). This antibiotic has a broad spectrum and an excellent activity 
against Gram-positive and Gram-negative bacteria (Murray et al., 2016). It is used to treat several 
infections, including UTI, osteomyelitis, gonococcal infections and chronic bacterial prostatitis 
(Emmerson, 2003). 
 
 
Figure 1.3: Ciprofloxacin. Antibiotic widely used (adapted from Nicolaou and Rigol 2017). 
 
1.1.3. Antibiotics resistance   
The increasing spread of bacterial resistance to antibiotics (Figure 1.4) at the community 
setting is promoted by several factors. The excessive and misuse of antibiotics in human medicine, 
in veterinary and in agriculture represent some of the behaviors responsible for selective pressure 
which enables the selection and spread of clones that carry antibiotic-resistance genes (Furuya 
and Lowy, 2006). Bacterial resistance is closely associated with excessive and prolonged use of 
antimicrobial agents in clinical practice. Prolonged therapy with antibiotics may lead to the 
development of resistance in microorganisms that initially are sensitive to antibiotics, but later 
can adapt gradually and develop resistance to these and consequently increasing the risk of 
mortality, increasing the costs and days of hospitalization (Giedraitienė et al., 2011). Threatening 
microbes causing infections in hospitals and in the community are overcoming 50% resistance 
rate over the world (Fair and Tor, 2014a; WHO, 2014b; Renwick et al., 2016). It was estimated 
that in 2050 the resistance to antibiotics will be responsible for 10 million deaths and for the loss 
of 100 trillion USD of the world's economic outputs (O’Neill, 2016). Also, the use in agriculture and 
veterinary for growth promotion, feed efficiency, and routine disease prevention purposes in 
animal agriculture is another important reason for the spread of resistant bacteria (Giedraitienė 
et al., 2011). Over the years, the antibiotics have been used abusively and incorrectly. Annually, 
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large amounts of antibiotics are released in the environment for not being completely 
metabolized when used in humans, animals (veterinary medicine) or in other applications 
(Marinho et al., 2016). 
 
 
 
Figure 1.4: The spread of antibiotic resistance (Reardon, 2015). 
 
Antimicrobial resistance can be intrinsic or acquired. The intrinsic resistance is the innate 
ability of all bacterial species to resist activity of a particular antimicrobial agent through its 
inherent structural or functional characteristics, which allow tolerance of a particular drug or 
antimicrobial class (Cox and Wright, 2013). Acquired resistance occurs when a microorganism 
obtains the ability to resist the activity of a particular antimicrobial agent to which it was 
previously susceptible. Unlike intrinsic resistance, traits associated with acquired resistance are 
found only in some strains or subpopulations of each particular bacterial species. The acquired 
resistance can result from the mutation of genes involved in normal physiological processes and 
cellular structures, from the acquisition of foreign resistance genes or from a combination of 
these two mechanisms. The most common way to acquired resistance is through horizontal gene 
transfer between strains and species (Bockstael and Van Aerschot, 2009). There are three main 
different mechanisms of horizontal gene transfer in bacteria (Figure 1.5), these being:  
 
a) Transformation is the process by which bacteria capture and incorporate 
segment of DNA (exogenous or foreign) from bacterial lysates that carry 
    
10 
 
antimicrobial resistance genes. The gene resistance may be incorporate into 
chromosome or plasmid in the recipient cell, giving rise to a resistant cell 
(American Society for Microbiology, 2005; Murray et al., 2016). 
 
b) Conjugation occurs when two bacteria cells are close. DNA transfer is 
unidirectional, from the donor cell to the receptor cell, and occurs through a 
bridge-like structure known as pilus. This mechanism occurs typically between 
members of the same or related species. Gene transfer is performed through 
plasmids or integrative conjugative elements. Many of these carry genes for 
antimicrobial resistance (American Society for Microbiology, 2005; Heuer and 
Smalla, 2007; Murray et al., 2016) 
 
c) Transduction is the transfer of genetic information by which non-viral DNA can be 
transfer mediated by phages. Many phages infect only a narrow range of hosts. 
This mechanism has the advantage of not requiring cell-cell contact (American 
Society for Microbiology, 2005; Heuer and Smalla, 2007; Murray et al., 2016). 
 
 
Figure 1.5: Mechanisms of bacterial gene transfer (Murray et al., 2016). 
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Bacteria can protect themselves through mutation in the target site, enzymatic 
modification or degradation of the antibiotic, efflux of antibiotics, reduced permeability to 
antibiotics and acquisition of alternative metabolic pathways (Vranakis et al., 2014). 
In last decades, the development of new antibiotics has lagged behind the acquisition of 
antibiotic resistance in bacteria (Hede K, 2014). Therefore, new antimicrobial strategies are 
essential to effectively control antibiotic resistance. Recently, phages have received much 
attention as an alternative and/or supplementary approach to antibiotics (Weber-Dabrowska et 
al., 2016; Anne-sophie and Benoit, 2017) because of their efficacy of bacterial inactivation, host 
specificity, safety and low costs (Parisien et al., 2008). 
  
1.2. Phage therapy in the inactivation of pathogenic bacteria 
Phage therapy consists in the utilization of phages to inactivate pathogenic bacteria. Phages 
were discovered by the early 1920s and their infectious cycles were understood by that time, but 
after antibiotic advent the interest in phage therapy declined in the western world (Sulakvelidze 
et al., 2001). Nevertheless, in former Soviet Union and Eastern Europe, this method of treatment 
was continuously used to treat and prevent bacterial infection diseases (Sulakvelidze et al., 2001). 
Recently, the emergence of pathogenic bacteria resistant to antibiotics, has motivated the 
western scientific community to reevaluate phage therapy as an alternative option for the 
treatment of bacterial infections (Wittebole et al., 2014). In a time when bacterial resistance to 
antibiotics is increasing, the use of phages has different advantages, along with relatively few 
disadvantages. 
Phages production is simple, but in the past when this therapy was first applied clinically 
side effects were difficult to control. There are some requirements, not taken into account in the 
past, in the production of phages that are: phages must be free from microorganisms (purified), 
lytic and can not transduce virulence factor genes of the host; stability over storage and during 
application must be tested; the host range need to be well known; to avoid resistance and toxin 
transmission to bacteria, genome sequencing should be done; the receptor of the phage must be 
known. In a population of 106 to 108 there is a great possibility of spontaneous mutants resistant 
to phages displaying an altered receptor; and amenability to scale up (Skurnik and Strauch, 2006). 
The difficulties of acceptance and implementation of phage therapy as an alternative to 
combating of infections are due to (a) differences in biological, physical, and pharmacological 
properties of phages compared to conventional antimicrobials, (b) the need to employ phage 
cocktails due to high phage specificity and (c) current approval processes for antimicrobial agents 
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that are based on chemically derived drugs and which are therefore less suitable for phages 
(Cooper et al., 2016). Phage-derived enzybiotics are already suitable for the current approval 
processes as therapeutic proteins, however, phage therapy may require other pathways of 
approval (Cooper et al., 2016; Abedon et al., 2017; Aminov et al., 2017). 
 
1.2.1. Bacteriophages 
Phages were discovered independently by Frederick W. Twort in 1915 and by Felix d’Herelle 
in 1917 (Sulakvelidze et al., 2001). Felix d’Herelle named them phages (formed from “bacteria” 
and “phagein” that means “to eat”, in Greek) and developed the method of quantification of 
viruses and some theories, including the replication cycle of the phage (Sulakvelidze et al., 2001). 
After the discovery of phages, d’Herelle introduced the term phage therapy, that was regarded as 
a possible method of treatment against bacterial infectious diseases (Sulakvelidze et al., 2001). 
Soon after its discovery, phages began to be exploited and used to control infections by 
pathogenic bacteria (Abedon et al., 2011).  
Phages are viruses that infect only prokaryotes (bacteria and archaea) (Skurnik and Strauch, 
2006; Ceyssens and Lavigne., 2010), resulting usually in propagative lyses (lytic cycle) or 
lysogenization (lysogenic cycle) of the infected cell (Azizian et al., 2013; Borie et al., 2014; Teng-
hern, Kok-gan and Han, 2014). Lytic phages may be candidates for phage therapy, because they 
replicate fast within their hosts and lyse them (Azizian et al., 2013). Phages can be defined as a 
capsid-encoding organism that is composed by proteins and nucleic acids, self-assembles in a 
nucleocapsid that uses a ribosome-encoding prokaryotic organism for the completion of its life 
cycle (Raoult and Forterre, 2008). 
Phages are the most abundant organisms in the biosphere and they are a ubiquitous 
feature of prokaryotic existence (total number estimated to be 1030-1032) (Fuhrman, 1999; Clokie 
et al., 2011; Bhardwaj et al., 2015). The presence of the phages in the biosphere results in phages 
coevolving with their host bacteria and provide the earth’s ecological equilibrium in several 
environmental or ecological niches (Vos and Pirnay, 2015). 
The phages present a variety of different morphological types, but the majority displays a 
capsid, collar and tail (Figure 1.6) (Hanlon, 2007). Phages contain a core nucleic acid encapsulated 
with a protein or lipoprotein capsid which is connected with a tail that interacts with various 
bacterial surface receptors via the tip of the tail fibers. The capsid is a protein shell often in the 
shape of an icosahedron and usually comprises double-strand (dsDNA), but there are phages with 
single stranded DNA (ssDNA), single-stranded RNA (ssRNA) or double-stranded RNA (dsRNA) and 
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can vary between 17 kb and 500 kb (Melo et al., 2017). The capsid is organized into capsomeres, 
whose main function is to protect the genetic material (Sharma et al., 2017). The tail may or may 
not be a contractile structure to which six fibers are usually connected, containing receptors on 
their ends that recognize binding sites on the surface of the bacterial cell. Phage tails are very 
varied in DNA content and composition, dimensions, structure and physiology (Ackermann, 2003). 
However, not all phages have tails and tail fibers and in this situation other attachment 
mechanisms are present (Goodridge and Abedon, 2003; Hanlon, 2007).  
 
 
 
Figure 1.6: Representation of a typical bacteriophage (adapted from Nobrega et al. 2015). 
 
1.2.2. Taxonomy of bacteriophages  
The International Committee on Taxonomy of Viruses (ICTV) is responsible for the 
classification of the viruses (Aiewsakun and Simmonds, 2018). Bacteriophage taxonomy is based 
on morphological (size and shape) and molecular characteristics (type of nucleic acid) (Table 1.1). 
Phages are tailed, polyhedral, filamentous, or pleomorphic (Ackermann, 2003, 2007). 
Nowadays, it can be found around 4 families, 22 subfamilies and 164 genera, belonging to 
the Caudovirales order. Over 96% of phages are tailed and belong to Caudovirales order, and are 
divided into four families: (1) Myoviridae, in which viruses have a contractile tail constituted by 
hem, a central tube and a big capsid head (~150 nm), (2) Siphoviridae, in which viruses have long 
not contractible tails, and a relatively small capsid head (~50-60 nm), (3) Podoviridae, in which 
viruses have no contractile tail and have short tails and a small capsid head (~50-60 nm) and (4) 
Ackermannviridae (Ackermann, 2007; Comeau et al., 2012; Rossmann, 2013; Cruz-Flores and 
Cáceres-Martínez, 2016; ICTV, 2017; King et al., 2018). Ackermannviridae was recently approved, 
taking into account the DNA sequencing (ICTV, 2017). The other non-tailed phages (represent less 
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than 4%), are classified into ten families, and are cubic, filamentous, or pleomorphic and contain 
double-stranded or single-stranded DNA or RNA as the genome. 
 
Table 1.1: Taxonomy and properties of phage families (adapted from Ackermann and Prangishvili, 2012; 
Mäntynen et al., 2015; Pereira, 2016; ICTV, 2017). 
Order Shape Families Nucleic acid Characteristics 
Caudovirales Tailed 
Myoviridae 
dsDNA, Linear 
Contractile tail 
Siphoviridae 
Long, non-
contractile tail 
Podoviridae 
Short, non-
contractile tail 
Ackermannviridae * 
Unassigned 
Polyhedral 
Microviridae ssDNA, circular Icosahedral capsid 
Corticoviridae 
dsDNA, circular, 
superhelical 
Icosahedral capsid 
with lipid layer 
Tectiviridae dsDNA, linear 
Icosahedral capsid 
with inner 
lipoprotein vesicle 
Leviviridae ssRNA, linear 
Quasi-icosahedral 
capsid 
Cystoviridae 
dsRNA, linear, 
segmented 
Enveloped, 
icosahedral 
capsid, lipids 
Pleomorphic 
Plasmaviridae 
ssDNA, circular, 
superhelical 
Pleomorphic, 
envelope, lipids, 
no capsid 
Fuselloviridae 
dsDNA, circular, 
superhelical 
Envelope, lipids, 
no capsid 
Filamentous 
Inoviridae ssDNA, circular 
Rod-shaped with 
helical symmetry 
Ligamenvirales 
Lipothrixviridae dsDNA, linear 
Enveloped 
filaments, lipids 
Rudiviridae dsDNA, linear Helical rods 
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*Not found  
 
1.2.3. Life cycle  
 The life cycles of phages typically, can be classified broadly into categories lytic (virulent) 
and lysogenic (temperate) cycles (Sharma et al., 2017). There is a third way by which phages can 
also interact with their hosts, the pseudolysogenic cycle (Figure 1.7). 
A prokaryotic virus has various steps throughout the life cycle and these are common to all 
virus. The steps are adsorption, separation of nucleic acids from protein coat, expression and 
replication of the nucleic acids, virion assembly, release and transmission (Weinbauer, 2004). 
In the lytic cycle, the host cell is injected with the genome of the phage (Hogg, 2013). These 
need to multiply themselves to cause lysis of the host cell to release the newly formed phages 
(Skurnik and Strauch, 2006). On the surface of the host cell, phages adsorb to specific receptor 
sites on the surface of the host cell and subsequently form an irreversible attachment. Capacity to 
recognize and attach to receptor molecules on the cell surface mainly dictates the host range of a 
phage (Hanlon, 2007).  
The penetration of tail occur through cell walls degraded enzymatically driving to the 
insertion of phage nucleic acid into the cytoplasm of the host (Weinbauer, 2004). For DNA phages, 
once inside the cell, the bases of the phage nucleic acid are often modified to protect against the 
attack by restriction enzymes and cellular nucleases. The viral genome is transcribed by RNA 
polymerases of the host cell, producing premature mRNA, that will take over the metabolic 
machinery of the host and redirect the metabolic processes to the production of new viral 
components, such as nucleic acid and proteins. After the replication and assembly of new phage 
particles within the host cell, the new phages are released to the environment (Hanlon, 2007; 
Wittebole et al., 2014). Most of the dsDNA develop lytic enzymes that attack the bacterial 
peptidoglycan, for the dissemination of its offspring phages (Fischetti, 2005). These phages 
produce a lytic enzyme, usually called endolysin or muralytic enzymes, that are produced within 
the cytoplasm but require another enzyme, capable of permeabilize the membrane, designated 
holin. Endolysin need this protein, because most of these enzymes lack a secretory signal 
sequence and, in addition, this protein gives access to murein (Young et al., 2000). The holin 
rupture the membrane,  allowing the lysin to degrade the peptidoglycan (Young et al., 2000; 
Fischetti, 2005). It also controls the timing of the cell lysis which leads to a disruption of the 
membrane and the release of the phage progeny (Fischetti, 2005). The filamentous phage can 
escape the host cell by extrusion through the cell wall without causing the destruction of the host, 
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however these phages did not present relevance for phage therapy (Hanlon, 2007). The period of 
time between the attachment of a phage particle to the cell surface and the release of the newly 
synthesized phages is called the latent period, sometimes also known as the burst time (Hogg, 
2013). 
In the lysogenic cycle, the phage integrates its own DNA into the genome of the host (Wang 
and Goldenfeld, 2010). A copy of the phage genome is maintained in a suppressed state within 
the host genome and replicates with the host chromosome (Skurnik and Strauch, 2006; Hogg, 
2013). The temperate phages induce a state of lysogeny in the bacterial host (Hanlon, 2007) and 
they do not enter automatically on a lytic cycle (Skurnik and Strauch, 2006; Hogg, 2013). Cells may 
divide multiple times but, occasionally, one will spontaneously lyse and release progeny phage 
(Gill and Hyman, 2010). The prophage enters the lytic cycle when forced by a given stimuli, such 
as pollution, starvation and others. These phages can transfer DNA host fragments, which may 
contain antibiotic resistance and therefore the only phages used in phage therapy are the lytic 
ones (Wang and Goldenfeld, 2010; Rossitto et al., 2018).  
The pseudolysogeny cycle, or false lysogeny, is defined as a phenomenon where there is a 
continuous production of phage in the presence of high host cell abundance (Ackermann and 
DuBow, 1987). In this cycle the bacteriophage lysis does not outcome in total host death and the 
abundance of phage coexists with exponential host growth. This may be the outcome of a mixture 
of resistant and sensitive host cells and/or a mixture of virulent and temperate phages. Thus, the 
phage may proceed with lytic infection or enter a dormant intracellular phase, with no integration 
of the phage genome into host cell replicons (Wommack and Colwell, 2000). Pseudolysogeny is an 
environmental condition in which the bacterial cell coexists in an unbalanced relationship with 
infective viruses (Ripp and Miller, 1997, 1998). Under these conditions, host cells do not offer 
enough energy in order to phage incoming into a true lysogenic or lytic condition (Williamson et 
al., 2001). 
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Figure 1.7: Schematic representation of phage life cycles (adapted from Weinbauer, 2004). 
 
1.2.4. Phage therapy applications  
Phage therapy has been studied to be applied or is even already applied in several areas, 
such as medicine (Sunagar et al., 2010; Kumari et al., 2011; Rahmani et al., 2015; Zhang et al., 
2017), food safety (Pereira et al., 2017a; Sharma et al., 2017), veterinary (Hawkins et al., 2010; 
Suresh et al., 2017) and aquaculture (Silva et al., 2014a, 2016; Kalatzis et al., 2016; Wang et al., 
2017). Also, it has been used to treat wastewater (Withey et al., 2005; Beheshti et al., 2015). 
 
1.2.4.1. Clinical applications of phage therapy 
Through the summer of 1919, d'Herelle applied phages in five children with bacillary 
dysentery admitted at the hospital Necker-Enfants-Malades in France, achieving therapeutic 
success in all cases (Dublanchet and Bourne, 2007). 
Clinical phage therapy is allowed for routine use in a limited number of countries, however, 
the corresponding data from these efforts is limited. Formerly, in phage therapy, clinical use was 
performed prior to animal testing, but in the modern era, this therapy has to adopt current 
standards of drug development, that is, in which animal testing by need precedes clinical use 
(Abedon et al., 2017). 
The Republic of Georgia is the one place in the world where phage therapy is regularly used 
in a number of hospitals and clinics for both prophylactic and treatment purposes.  Most of the 
available phages have been associated with the Eliava Institute. The main focus of this institute 
has been on therapeutic phage cocktail formulation, characterization, production and 
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implementation. Hirszfeld Institute, in Poland, is another important source of information.  In this 
Institute, researchers have developed individual therapeutic phages and reinforced their use by 
local physicians for a diversity of applications where antibiotics were unsuccessful (Kutter et al., 
2010).  
Researchers are evaluating the use of phage in clinical trials in humans (Table 1.2), 
however, only a limited number of clinical trials have been conducted so far, which is surprising 
given the growing concern around antibiotic resistance. The reason for the lack of data is varied 
and concern about the safety of phage use in humans has been an obstacle to the development of 
phage therapy in the western world, although there are already commercially available phage 
preparations available in Russia and Georgia for decades (Vandenheuvel, Lavigne and Brüssow, 
2015). 
 
Table 1.2: Overview of safety and clinical phage trials (Adapted from Vandenheuvel et al., 2015).  
Trial 
phase 
Experimental 
details 
Target bacterium Observations Refs 
Safety 
trials 
Exposure to 
phages (e.g., 
environment, skin, 
gut, food 
consumption) 
NA 
No indication of 
health risks was 
found. 
Brüssow, 2001; 
Desiere et al., 
2001; Suttle, 
2005; Reyes et 
al., 2010; Oh et 
al., 2014 
Animal 
experiments 
E. coli 
Oral administration of 
T4 did not affect the 
microbiota of mice; 
no phage was found 
in the blood or 
organs. 
Chibani-
Chennoufi et 
al., 2004a; 
Weiss et al., 
2009 
Human 
experiments 
NA 
Oral administration of 
T4 did not result in 
anti-T4 antibodies or 
liver damage. 
Bruttin and 
Brüssow, 2005 
    
19 
 
Phase I/II 
clinical 
trials 
Oral 
administration of 
phage cocktails to 
healthy adults and 
children 
NA 
No adverse effects 
were observed. 
Sarker et al., 
2012 
Intravenous 
administration of 
ϕX174 to HIV 
patients 
NA 
No adverse effects 
were observed. 
Ochs et al., 
1971; Fogelman 
et al., 2000; 
Rubinstein et 
al., 2000 
The Intralytix trial: 
phage therapy on 
venous leg ulcers 
E. coli;  
Pseudomonas 
aeruginosa;  
S. aureus 
No adverse effects 
were observed. 
Rhoads et al., 
2009 
The Belgian 
Military Hospital 
trial: phage 
therapy on burn 
wounds 
P. aeruginosa; 
S. aureus 
No adverse effects 
were observed; the 
bacterial load 
remained unchanged. 
Merabishvili et 
al., 2009; Rose 
et al., 2014 
The Polish case 
studies 
Suppurative 
multidrug-resistant 
infections 
No serious adverse 
effects observed; the 
success rate was high. 
Weber-
Dabrowska et 
al., 2000 
The Biocontrol 
trial: phage 
therapy against ear 
infections 
P. aeruginosa 
No adverse effects 
were observed; 12 of 
42 patients showed 
significant 
improvements. 
Wright et al., 
2009 
The Nestlé trial: 
phage therapy 
against diarrhea 
E. coli 
The trial was stopped 
because of the 
absence of a 
therapeutic effect; no 
adverse effects were 
Chibani-
Chennoufi et 
al., 2004b 
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observed. 
Phase III 
clinical 
trials 
The Eliava trial: 
phage therapy 
against Shigella 
dysentery 
Shigella spp. 
A significant decrease 
in disease incidence 
was observed. 
Babalova et al., 
1968; 
Sulakvelidze et 
al., 2001 
NA - not applicable 
 
1.2.4.2. Commercialization of phage products 
D´Herelle developed, in the commercial laboratory in Paris (later known as the company 
L'Oréal), products based on phages. These products were called Bacté-coli-phage, Bacté-rhino-
phage, Bacté-intesti-phage, Bacté-pyo-phage and Bacté-staphy-phage. In the 1940, Eli Lilly 
Company (Indianapolis, Ind.) prepared seven phage products to treat abscesses, septic wounds 
and vaginitis, mastoid infections and respiratory tract infections caused by staphylococci, 
streptococci, E. coli and others microorganisms (Sulakvelidze et al., 2001). Phages may be 
versatile in terms of formulation development. They can be applicated in many forms, like as 
liquids, creams, impregnated into solids and others, and are suitable for most routes of 
administration (Loc-Carrillo and Abedon, 2011). Presently, some bacteriophage products have 
been licensed and approved for human application (Guang-Han et al., 2016) and others are in 
development (Table 1.3). 
Some phage therapeutic products, such as Phage BioDerm, use the combination of phage 
and antibiotics. Phage BioDerm is used in humans and is a biodegradable, non-toxic polymer 
impregnated with phages and the antibiotics ciprofloxacin and benzocaine. Conventional 
treatment was used to treat patients with ulcers and wounds, but it was not successful. After 
that, patients were treated with Phage BioDerm and a success rate of 70% was observed (Guang-
Han et al., 2016). 
 
Table 1.3: Some phage based products developed or in development for treatment of human disease 
(Adapted from Cooper et al., 2016).  
Company Product Target Application Type Company website 
Micreos Staphefekt S. aureus Topical Endolysin 
https://www.staphefekt 
.com 
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AmpliPhi 
AB-SA01 S. aureus 
Intravenous, 
intrasinal and 
topical Phage 
http://www.ampliphibio 
.com 
AB-PA01 P. aeruginosa 
Intravenous 
and inhaled 
Technophage 
TP-102 
* 
Ulcers 
Phage 
http://www.technophage 
.pt 
TP-122 Respiratory 
TP-164 Infection 
TA-111 
Neuroscience 
TZ-113 
TZ-161 
TA-111/16 
TA-101/16 
Immunology 
TA-141 
Pherecydes 
Pharma 
PP021 E. coli Burn and skin 
Phage 
http://www.pherecydes-
pharma.com 
PP1131 
PP1231 
 
Pseudomonas 
 
Burn, skin 
and 
respiratory 
Tract 
infection 
PP2351 Staphylococcus 
Bone, Joint 
and 
Prosthesis 
PhagoBurn 
P. aeruginosa 
and E. coli 
Skin 
infections 
PneumoPhage P. aeruginosa 
Respiratory 
tract 
infections 
Phosa S. aureus 
Bone and 
joint or 
diabetic foot 
ulcer 
infections 
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Avid Biotics Avidocin 
Clostridium 
difficile 
Infections 
Phage 
derived 
http://www.avidbiotics 
.com 
ContraFect 
CF-301 S. aureus 
Bloodstream 
infections 
Phage 
derived 
lysins 
http://www.contrafect 
.com 
CF-296 S. aureus * 
GN lysins P. aeruginosa * 
BP lysins 
Streptococcus 
pneumoniae, 
Enterococcus 
faecalis, 
Bacillus 
anthracis and 
Group B 
Streptococcus 
* 
CF-404 Influenza 
Seasonal and 
pandemic 
strains of 
human 
influenza 
Pharmacy 
Eliava 
INTESTI 
Bacteriophage 
Shigella, 
Salmonella, E. 
coli, Proteus, S. 
aureus, P. 
aeruginosa and 
E. faecalis 
Inflammatory 
and enteric 
infectious 
diseases 
Phage 
http://bacteriophage 
pharmacy.com 
PYO 
Bacteriophage 
S. aureus, 
Streptococcu, 
E. coli, P. 
aeruginosa and 
Proteus 
Fersis 
Bacteriophage 
Staphylococcus 
and 
Streptococcus 
SES 
bacteriophage 
Staphylococcus, 
E. coli and 
Streptococcus 
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Enko 
Bacteriophage 
Shigella, 
Salmonella, E. 
coli and 
Staphylococcus 
*Information not available 
 
1.2.4.3. Other applications of phage therapy 
When it comes to the use of phage therapy in a clinical context, the approval timelines and 
long product developments in Western regulatory frameworks are obstacles. Because of this, 
many companies and researchers have turned to the area of food safety, agriculture and others. 
Environmental Protection Agency (EPA), United States Department of Agriculture (USDA) and 
Food and Drug Administration (FDA) have approved successful phage-based products that have 
been developed by several of these companies. Some of these products, which are used as 
sterilizing agents for processed foods are, for example, ListShieldTM and LISTEXTM P100 (Lu and 
Koeris, 2011). In food safety, phage therapy can be applicated to restrict bacterial contamination 
on several foods such as chicken flesh, meat, fruits, and vegetables (Sharma et al., 2017). 
 
1.2.5. Advantages and disadvantages of phage therapy  
Phage therapy has several advantages over antibiotics. Antibiotics have a low specificity 
(greater spectrum of action), compared to phages, and may cause side effects to the drug 
recipient, such as secondary infections, the appearance of resistant bacteria and allergies. 
However, phage specificity also may be a disadvantage, since detecting the causative agent of the 
infection may be delayed and may aggravate the condition of the patient. This obstacle can be 
overcome using a mixture of different phages (El-Shibiny e El-Sahhar 2017; Pereira et al. 2016a)  
Phages do not affect the cells of mammals because they target only bacterial cells (Golkar et 
al., 2014), with phage therapy being safe and relatively free of side effects (Weber-Dabrowska et 
al., 2016).  
Antibiotics may not be effective and can be metabolized and excreted from the body without 
the drug being able to reach the site that is being infected. On the other hand, the phages are 
widely spread throughout the body after being administered systemically, reaching the infected 
site (El-Shibiny and El-Sahhar 2017) and replicating in that location (Golkar et al., 2014). The very 
small size of phages allows them to go to body sites that are not reached by antibiotics (Wittebole 
et al., 2014; El-Shibiny and El-Sahhar, 2017). The exponential multiplication of phages at the site 
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of infection makes treatment less frequent and at lower doses compared to treatment using 
antibiotics (El-Shibiny and El-Sahhar 2017). One dose is enough (Vieira et al., 2012). Phages can be 
used to treat infections caused by bacterial strains resistant to antibiotics, including multidrug 
resistant strains (Weber-Dabrowska et al., 2016). 
Phages are prevalent in nature and their acquisition and selection is very fast compared to the 
development of antibiotics, which can take several years until they have an effective drug. In 
addition, the cost of producing antibiotics is much higher (El-Shibiny and El-Sahhar 2017).  
Despite the many advantages of phage therapy, it also has several disadvantages, such as the 
lack of established protocols for dose, frequency, duration and route of administration of the 
treatment, lack of properly documented clinical research, and poor knowledge of phage behavior 
in vivo. The side effects in the long run are unknown, and the purity and stability of phage 
preparations are doubtful, if sufficient quality control information is not available (El-Shibiny and 
El-Sahhar 2017). The lack of legislation is another limitation to wide use of phages to combat 
antibiotic-resistant bacteria (Weber-Dabrowska et al., 2016). An important disadvantage, when 
using phage therapy, is the development of phage-resistance by some bacteria (Gill and Hyman, 
2010; Silva et al., 2014a; Pereira et al., 2016a, 2017b).  
The most frequent cause of bacterial phage resistance appear to be genetic mutations 
affecting phage receptors, restriction modification or abortive infection associated with the 
presence of clustered regularly interspaced short palindromic repeats (CRISPRs) in the bacterial 
genome (Heller, 1992; Labrie et al., 2010). However, currently, the emergence of phage-resistant 
mutants also can be due to phenotypic resistance (Laanto et al., 2012; Vieira et al., 2012; Bull et 
al., 2014). This resistance may be: i) induced, the products of phage-lysed bacteria result in a 
change in uninfected bacterial gene expression, thus reducing adsorption; ii) intrinsic, reduced 
adsorption is due to a physiological or gene expression state that happens prior to the phage 
introduction; and iii) dynamic, degradation or blocking of bacterial receptors by phage proteins 
released during cell lysis (Bull et al., 2014).  
Phages  co-evolve with their hosts allowing them to overcome the resistance acquired by the 
bacteria (Wittebole et al., 2014; El-Shibiny and El-Sahhar, 2017). The acquisition of resistance to 
the phages can reduce the fitness of the host with consequences in growth and pathogenicity, 
mostly if the phage receptor is required for virulence. Phage resistance can be associated to lower 
virulence, making the resistant bacteria less virulent than the susceptible ones. However, possible 
alterations in the virulence of phages depend on the specific phage-host system (León and 
Bastías, 2015; Oechslin et al., 2017; Hill et al., 2018). Phage resistance may contribute to bacterial 
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elimination from the environment quicker than their wild-type parents (Bohannan et al., 1999; 
Brockhurst et al., 2005; Duarte et al., 2018). Resistance triggered by phages is a less important 
problem than that caused by antibiotics. Although bacteria can develop resistance to a 
determined phage, specific to them, there are always different phages with a similar target range 
(Wittebole et al., 2014; El-Shibiny and El-Sahhar, 2017). Contrarily to phages, antibiotics do not 
have the ability to evolve and escape the mechanisms of defense of the host. Moreover, phage 
resistance can be overcome more easily than resistance to antibiotics by using phage cocktails 
(Samson et al., 2013; Hill et al., 2018).  
 
1.3. Combination of antibiotics and bacteriophages in the inactivation of pathogenic 
bacteria  
While there are limitations to the use of phage and antibiotics as the sole agent for treating 
bacterial infections (Bull et al., 2002; Ul Haq et al., 2012), these bacterial viruses may be an 
effective adjunct to antibiotic treatment (Knezevic et al., 2013; Torres-Barceló et al., 2014; Torres-
Barceló and Hochberg, 2016; Valério et al., 2017)  (Table 1.4).  
The combination antibiotic-phage may have the advantage of reducing the development of 
resistance, particularly in multiple infections caused by bacteria (Kutateladze and Adamia, 2010; 
Kamal and Dennis, 2015; Torres-Barceló and Hochberg, 2016; Weber-Dabrowska et al., 2016), as 
well as stimulate the increase of the production of phage and/or their activity and increases the 
efficacy of killing bacteria (Kamal and Dennis, 2015). This evolution can be explained by the fact 
that (Figure 1.8): 
 (i) Bacteria resistant to one or both can emerge, but grow slowly due to costs and/or are 
fewer pathogenic than sensitive bacteria 
(ii) Double-resistant bacteria do not emerge due to trade-offs between resistance 
mechanisms. A direct negative interaction between mechanisms of resistance can be a powerful 
limitation on their evolution.  
(iii) If they are applied sequentially then double mutants (resistant to both antibiotic and 
phages) are extremely rare or absent. Synergy may result from low bacterial densities dropping 
the probability of the emergence of resistance mutations (Torres-Barceló and Hochberg, 2016).  
Antibiotics and phages could be applied sequentially, which might limit the emergence of 
double-resistant mutants (Imamovic and Sommer, 2013; Moulton-Brown and Friman, 2018). 
Torres-Barceló et al. (2014) suggest the existence of an optimal window of opportunity in the 
implementation of combined therapies to restrain pathogens. They observed that when a specific 
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time delay in antibiotic introduction is applied, regardless of antibiotic dose and resistance to 
either antibiotics or phages, bacterial density is reduced. This delay allows the phages to have 
their strongest impact on bacterial population density prior to the introduction of antibiotic 
(Torres-Barceló et al., 2014). 
Some studies demonstrated that phage-antibiotic combinations can cause the same 
resistance than phage and antibiotic introduced individually (Verma et al., 2009; Zhang and 
Buckling, 2012; Torres-Barceló et al., 2014). The interaction between phages and antibiotics 
during extensive periods of time may result in the emergence of phage-resistant and growth of 
bacterial density (Kumari et al., 2010; Nouraldin et al., 2016). However, it was also found that 
bacterial density does not increase in vivo, since the combination of phage and host defenses, 
after phage therapy, is enough to keep the bacterial density under the lethal limit (Levin and Bull, 
2004). 
Although there are studies using the combination antibiotic and phages to control 
problematic bacteria, these are still few and the existing ones determine only resistance to 
antibiotics and not to phages. Valério et al. (2017) tested not only the resistance to four 
antibiotics, but also studied the resistance to phages with and without antibiotics. They found 
that phages limit the emergence of antibiotic resistant variants in combined treatment, 
independently of the type and mechanisms of action of the four antibiotics. However, further 
studies are needed, in particular with addition of phage and antibiotics sequentially. 
 
 
Figure 1.8: Phage-antibiotic synergy mechanisms (Torres-Barceló and Hochberg, 2016). 
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There are some terms used to describe the effects of combined treatment (Piggott et al., 
2015; Baeder et al., 2016) (Table 1.4). According to the literature, combined effect can be the sum 
(additive), smaller than the sum (antagonistic) and greater than the sum (synergic), of the 
individual effects working in the same direction. Successful treatment is most likely for synergy, 
however simple additives may also get it, particularly when the host immune system is involved as 
a third member in the control (Crain et al., 2008; Torres-Barceló and Hochberg, 2016). Phage-
antibiotic synergy is defined as the phenomenon whereby sub-lethal concentrations of certain 
antibiotics can substantially stimulate the host bacteria’s production of virulent phage (Comeau et 
al., 2007; Kaur et al., 2012; Ryan et al., 2012; Torres-Barceló and Hochberg, 2016). The synergism 
effect of the antibiotic-phage combination has no direct association with the type of antibiotic 
(Torres-Barceló et al., 2016) and is not affected by the antibiotic resistance status of the target 
cell (Kamal and Dennis, 2015). Contrarily to that, Valério et al. (2017) observed that the efficacy of 
the combination of phages and antibiotics depends on the antibiotic resistance status of the 
bacteria to the used antibiotic and of the antibiotic type (bactericide or bacteriostatic). From an 
evolutionary understanding, the logic of combining phages and antibiotics is that two different 
selective pressures are most likely to kill both nonresistant (susceptible to antibiotics) and 
antibiotic-resistant (susceptible to phages) pathogen genotypes, and are probably better than 
when used separately (Torres-Barceló and Hochberg, 2016). 
 
Table 1.4: Some studies showing antibiotic-phage encouraging  effects to control problematic or model 
bacteria (Adapted from Torres-Barceló & Hochberg, 2016). 
Bacteria 
Phage 
Family 
Antibiotic Effects Refs 
P. aeruginosa 
Not 
described 
Ciprofloxacin, 
meropenem 
-Highly synergistic 
effect 
- Inhibited 
regrowth of phage-
resistant mutants 
Oechslin et al., 
2017 
E. coli 
Not 
described 
Ciprofloxacin, 
ampicillin, 
piperacillin, 
kamanycin, 
-Decreased the 
bacterial counts 
- Decrease of 
emergence resistance 
Valério et al., 2017 
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tetracycline, 
chloramphenicol 
to phages 
P. aeruginosa 
Not 
described 
Amikacin 
-Showed biofilm 
eradication 
Nouraldin et al., 
2016 
P. aeruginosa Podoviridae 
Carbenicillin, 
gentamicin, and 
trimethoprim 
- Limited bacterial 
density recovery 
- Reduction of 
antibiotic resistance 
levels 
Torres-Barceló et 
al., 2016 
Burkholderia 
cepacia 
Myoviridae 
Meropenem, 
ciprofloxacin, 
tetracycline 
- Phage-antibiotic 
synergy 
-Increased survival of 
larvae 
Kamal and Dennis, 
2015 
E. coli and P. 
aeruginosa 
Not 
described 
Tobramycin 
-Reduce of emergence 
resistance to 
antibiotic 
Coulter et al., 2014 
P. aeruginosa Podoviridae Streptomycin 
-Decreased of 
bacterial density 
- Limited resistance to 
antibiotic and phages 
Torres-Barceló et 
al., 2014 
P. aeruginosa Siphoviridae Cefotaxime 
-Synergistic reduction 
of bacterial growth 
Knezevic et al., 
2013 
S. aureus Myoviridae Linezolid 
-Stopped MRSA 
hindpaw foot 
infection 
-Decreased bacterial 
density 
Chhibber et al., 
2013 
Pseudomonas 
Fluorescens 
Podoviridae Kanamycin 
-Decreased bacterial 
survival 
-Limited resistance to 
antibiotic 
Zhang and 
Buckling, 2012 
S. aureus Myoviridae Gentamicin 
-Decreased bacterial 
density 
Kirby, 2012 
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-Prevention of phage-
resistant variants 
E. coli 
Not 
descibed 
Cefotaxime 
-Enhanced eradication 
of bacterial biofilms 
Ryan et al., 2012 
Klebsiella 
pneumoniae 
Podoviridae 
(T7-like) 
Ciprofloxacin 
-Eradication of 
bacteria 
-Prevention of 
resistant variants to 
antibiotic 
Verma et al., 2009 
E. coli 
Not 
descibed 
Ofloxacin, 
gentamicin, 
ampicillin 
- Reduced number of 
antibiotic-resistant 
variants 
Lu and Collins, 
2009 
E. coli Myoviridae Cefotaxime 
- Phage-antibiotic 
synergy 
-Eradication of 
bacterial biofilms 
Comeau et al., 
2007 
E. coli 
Not 
described 
Enrofloxacin 
-Total protection of 
birds 
Huff et al., 2004 
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Chapter 2 – Sequential combined effect of phages and antibiotics on 
the inactivation of E. coli 
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2.1. Abstract 
The emergence of antibiotic resistance in bacteria is a global concern and the use of 
bacteriophages alone or combined with antibiotics is attracting increasing attention as an 
alternative approach to inactivate resistant bacteria. However, phage-resistant mutants have 
been considered a major concern when phage treatment is employed. The aim of this study was 
to evaluate the effect of combined treatments of phages and antibiotics in the inactivation of 
Escherichia coli. E. coli is one of the main responsible for moderate and serious infections in the 
hospital and community environments, being involved in the rapid evolution of fluoroquinolones 
and third generation cephalosporin resistance. For this, ciprofloxacin at lethal and sublethal 
concentrations, added at different times (0, 6, 12 and 18 h), was tested in combination with the 
phage Ec-Bio to inactivate E. coli. The efficacy of the combined treatment varied with the 
antibiotic concentration and with the time of antibiotic addition, avoiding bacterial regrowth 
when the antibiotic was used at MIC and added after 6 h of phage addition, and causing less 
bacterial resistance than phages and antibiotics applied alone (4.0 x 10-7 for the combined 
treatment, 3.9 x 10-6 for the antibiotics alone and 3.4 x 10-5 for the phages alone). The combined 
treatment with phages and antibiotics can be effective in reducing the bacterial density, but also 
to prevent the emergence of resistant variants. However, the antibiotic concentration and the 
time of antibiotic application are essential factors to be considered in the combined treatment. 
 
Keywords: Bacteriophages, antibiotics, combination therapies, Escherichia coli, resistance 
 
2.2. Introduction  
Escherichia coli is a non-pathogenic commensal bacterium characterized by its diversity and 
versatility since it is able to colonize human and other animal intestines. However, this species 
developed some variants that colonize outside the gastrointestinal system. These strains harbor 
more virulence factors, causing severe diseases such as diarrhea, urinal tract infections, 
septicemia, pneumonia and meningitis (Cabal et al., 2016). Additionally, the development of 
resistance to antibiotics within intestinal and extra-intestinal E. coli strains is currently increasing, 
especially against beta-lactam antibiotics and to quinolones (Allocati et al., 2013; Iredell et al., 
2016). According to the World Health Organization (WHO), one of the most problematic areas of 
drug resistance is the rapid evolution of fluoroquinolones and third generation cephalosporin 
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resistance in Enterobacteriaceae, namely in E. coli, which is the main representative species of 
this family (Fair and Tor, 2014b; WHO, 2014). Actually, E. coli strains, namely antibiotic resistant 
strains, are among the main responsible for moderate and serious infections in the hospital and 
community environment (Allocati et al., 2013; Cabal et al., 2016). 
Infections with resistant bacteria, namely those caused by Gram-negative bacteria, are 
difficult to treat, causing severe illness and requiring costly and sometimes toxic alternatives, such 
as last resort antibiotics, such as colistin which is used against Gram-negative bacteria. However, 
bacterial strains resistant to last resort antibiotics have been isolated worldwide (Levine, 2006; 
Wang et al., 2018). The development of novel, but still conventional, antibiotics is not likely to 
solve the problem and it is probably only a matter of time until they will also be ineffective. 
Bacteria will inevitably find ways of resisting the conventional antibiotics, which is why new 
approaches are urgent to be used as alternative to antibiotics. 
The use of phages as antibacterial agents can be a very promising alternative for the 
treatment of infections, to be used alone or in combination with antibiotics. Phage treatment is 
based on the use of lytic phages to combat bacterial infections, including multidrug-resistant 
bacteria, and has many advantages compared to antibiotics, such as: phages persist as long as the 
targeted bacteria are present; are specific for their target bacteria, not effecting the host natural 
flora; and are not pathogenic for human (Almeida et al., 2009). Until the advent of antibiotics, 
phage therapy was widely used, especially in the Eastern Europe countries and recently, the 
emergence of pathogenic bacteria resistant to antibiotics, including multidrug resistant bacteria, 
has motivated the western scientific community to reevaluate phage therapy as a valid option for 
the treatment of bacterial infections (Sulakvelidze et al., 2001; Ackermann, 2003). Currently, the 
potential use of phage therapy in agriculture, veterinary biocontrol, food safety and in clinical 
treatment of human infections is also being studied (Mole and Maskell, 2001; Deresinski, 2009; 
Balogh et al., 2010; Gill and Hyman, 2010; Kutter et al., 2010; Mahony et al., 2011). However, a 
few studies have demonstrated that phages can be used to successfully prevent or control E. coli, 
even antibiotic resistant strains (Brüssow, 2005; Pererva, Miryuta and Miryuta, 2008; Rahmani et 
al., 2015) and, to the best of our knowledge, only one study, of our group, was done using the 
combination of phages and antibiotics to prevent the emergence of phage-resistant E. coli 
mutants (Valério et al., 2017). 
The emergency of phage-resistant mutants is nowadays a major concern regarding the use 
of phages to control bacterial infections. It has been shown that the use of phage cocktails can 
reduce the development of phage-resistant mutants (Pereira et al., 2016a, 2016b, 2017b; Duarte 
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et al., 2018) as well as the combined use of phages and antibiotics. A few studies reported a 
synergetic effect of the combined use of antibiotics and phages (Huff et al., 2004; Comeau et al., 
2007; Verma et al., 2009; Lu and Collins, 2009; Ryan et al., 2012; Zhang and Buckling, 2012; Kirby, 
2012; Chhibber et al., 2013; Knezevic et al., 2013; Torres-Barceló et al., 2014, 2016; Kamal and 
Dennis, 2015; Nouraldin et al., 2016; Chaudhry et al., 2017; Valério et al., 2017; Oechslin et al., 
2017), but only four of these showed that the combination of use of antibiotics and phages 
reduced the emergence of phage-resistant mutants (Verma et al., 2009; Kirby, 2012; Viertel et al., 
2014; Torres-Barceló et al., 2016; Oechslin et al., 2017). Oechslin et al. (2017) showed that the 
phages cocktail PP 1131 was active against Pseudomonas aeruginosa infection in endocarditis and 
highly synergistic with ciprofloxacin. In this study, phage-resistant mutants regrew after 24 h but 
were prevented by the combination with ciprofloxacin. Viertel et al. (2014) also observed a 
reduction of the combined therapy in the emergence of phage-resistant bacteria. These authors 
stated that the decrease in bacterial resistance to phages and/or antibiotics in dual therapy is due 
to the fact that a strain that is non susceptible to one antimicrobial agent can be eliminated by 
the second one. Torres-Barceló et al. (2016), showed a strong synergism effect of the combination 
of antibiotics and phages on Pseudomonas aeruginosa PAO1 population density and in limiting its 
recovery rate. Another study, Kirby, (2012) observed the that after the treatment with the 
combination of gentamicin and phage SA5, the phage-resistant isolates were extinct.  
In our previous study, we demonstrated the efficacy of the combination of the two 
therapies depends on the antibiotic resistance status of the targeted bacteria to the employed 
antibiotic and of the antibiotic type (bactericide or bacteriostatic), causing the same or less 
bacterial resistance than phages and antibiotics applied alone (Valério et al., 2017). So, in the 
present study, we extended our research to the use of a new phage and we studied the efficiency 
of the combination of the two therapies using different concentrations of antibiotic and phages to 
control the emergence of phage-resistant bacteria. Additionally, we also consider the influence of 
time of antibiotic addition in the inactivation of E. coli. For this, a bioluminescent E. coli (Alves et 
al., 2008) was selected as a model microorganism to evaluate in real-time phage therapy kinetics 
through the measurement of bioluminescence, thus avoiding the laborious and time-consuming 
conventional method of counting colony-forming units (CFU). The bioluminescent E. coli is 
resistant to ampicillin, chloramphenicol, kanamycin and piperacillin. 
 
2.3. Material and methods  
2.3.1. Bacterial strains and growth conditions 
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The bioluminescent E. coli used as phage host in this study was a genetically transformed 
E.coli Top10 (Alves et al., 2008). Other bacterial strains were used to determine the phage host 
range: Salmonella enterica serovar Typhimurium (ATCC 13311 and ATCC14028), Escherichia coli 
(ATCC 25922 and ATCC 13706), Aeromonas hydrophila (ATCC 7966), Vibrio fischeri (ATCC 49387), 
Vibrio parahaemolyticus (DSM 27657), Vibrio anguillarum (DSM 21597), Photobacterium 
damselae damselae (DSM 7482), Shigella flexneri (DSM 4782), Listeria innocua (NCTC 11288), 
Listeria monocytogenes (NCTC1194) and Aeromonas salmonicida (CECT 894), five strains of 
Salmonella enterica serovar. Enteriditis isolated from food (gently provided by Controlvet 
Laboratory), E. coli (AE11, AN19, AD6, AF15, BC30, AC5, AJ23, BN65, BM62), Enterobacter cloacae, 
Citrobacter freundii, Proteus mirabilis and Providencia sp and Pseudomonas aeruginosa isolated in 
previous works from water samples collected in Ria de Aveiro (Louvado et al., 2012; Pereira et al., 
2016b). 
The bioluminescent E. coli, used as phage host in the phage treatment experiments was 
grown in Tryptic Soy Broth (TSB, Liofilchem, Italy). A stock culture was stored at - 80 °C in 10% 
glycerol. Before each assay, stock culture of bioluminescent bacteria was aseptically inoculated 
into of 30 mL of TSB and was grown overnight at 25 °C at 120 rpm stirring. Then, an aliquot (300 
µL) of this culture was transferred to 30 mL of fresh TSB and was grown overnight at 25 °C under 
stirring (120 rpm), to reach 108 luminescence units (URLs), corresponding approximately 8 log 
colony forming units (CFU)/mL. 
The other bacterial strains used in this study, were maintained in solid Tryptic Soy Agar 
(TSA; Liofilchem, Italy) at 4 °C. Before each assay, one isolated colony was aseptically transferred 
to 30 mL of TSB and were grown and incubated as described above. Then an aliquot of this culture 
was subcultured in 30 mL of fresh TSB, as described above, to reach an optical density (O.D. 600 
nm = 0.8), corresponding to about 108-9 cells per mL. 
 
2.3.2. Correlation between bioluminescence and CFU  
An overnight culture of the bioluminescente E. coli (108 CFU/mL) was serially diluted (10-1–
10-8) in phosphate buffered saline [PBS, 137 mM NaCl (Sigma), 2.7 mM KCl (Sigma), 8.1 mM 
Na2HPO4·2H2O, 1.76 mM KH2PO4 (Sigma), pH 7.4]. The non-diluted (100) and diluted aliquots were 
read on a luminometer (1 mL) (TD-20/20 Luminometer, Turner Designs, Inc., Madison, WI, USA) to 
determine the bioluminescence signal. Simultaneously, 1 mL of each dilution was pour plated in 
TSA and incubated 25 °C for 24 h. Three independent experiments were performed, and the 
results were averaged.  
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2.3.3. Phage preparation  
The phage was isolated in a previous work from water samples collected from the Corte das 
Freiras aquaculture (Silva et al., 2014b). The phage was identified as a T4-like phage with 95% of 
homology with the Enterobacteriaceae phage Ec-Bio (accession number HM563683) (Silva et al., 
2014b). Silva et al. (2014b) demonstrated that the phage was effective in reducing the 
bioluminescent E. coli.  
The phage suspension was prepared from the phage stock isolated in previous works in SM 
buffer [0.1 M NaCl (Sigma), 8 mM MgSO4 (Sigma), 20 mM Tris-HCl (Sigma), 2% (w/v) gelatin, pH 
7.5]. Three hundred microliters of the phage stock were added to thirty milliliters of TSB with 
double concentration and one milliliter of the E. coli in exponential growth phase. Suspension was 
grown overnight and incubated at 25 ˚C at 50 rpm. The lysate was centrifuged at 13.000 rpm for 
30 min at 4 ˚C, to remove intact bacteria or bacterial debris. Phage suspensions were stored at 4 
°C. Phage suspension titer was determined by the double-layer agar method (Adams, 1959). 
Successive dilutions of the phage suspension were performed in PBS and 500 μL of each dilution 
together with 200 μL of fresh bacterial culture were mixed with 5 mL of TSB 0.6% top agar layer 
[30 g/L TSB (Liofilchem), 6 g/L agar (Liofilchem), 0.05 g/L CaCl2 (Sigma), 0.12 g/L MgSO4 (Sigma), 
pH 7.4], and placed over a TSA plate. The plates were incubated at 25 ºC for 12 h. After 
incubation, the number of plaques was counted and the results expressed as plaque-forming units 
(PFU)/mL. 
 
2.3.4. Phage host range determination and efficiency of plating analysis 
Phage host range was determined by spot test according Vieira et al. (2012) The plates 
were incubated at 25 °C and examined for plaques after 6 - 12 h. Bacterial sensitivity to a phage 
was established by a lysis cleared zone at the spot. According to the clarity of the spot, bacteria 
were differentiated into two categories: clear lysis zone (+) and not lysis zone (-). Then, efficiency 
of plating (EOP) was determined for bacteria with positive spot tests (occurrence of a clear lysis 
zone), using the double-layer agar method (Adams, 1959). The EOP was calculated (average PFU 
on target bacteria / average PFU on host bacteria) according to (Kutter, 2009). For each phage, 
three independent experiments were done. 
  
2.3.5. Antibiotic preparation  
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The antimicrobial agent used in this study was a ciprofloxacin (Cip, Sigma–Aldrich, St. 
Louis). Stock solutions were prepared following the manufacture instructions and used for 
preparation of the dilutions and stored in the freezer at - 80 °C. 
 
2.3.6.  Determination of Minimum inhibitory concentration (MIC) 
The minimum inhibitory concentration (MIC) for the antibiotic under study was determined 
in triplicate by the microdilution method in Mueller Hinton broth according to Clinical Laboratory 
Standardization Institute (CLSI) and European Committee on Antimicrobial (EUCAST) (CLSI, 2013; 
EUCAST, 2015). To determine the MIC of ciprofloxacin, different concentrations of the antibiotic 
(0.10 - 0.50 μg/mL) were prepared by serial dilution in Mueller Hinton broth. The tubes were 
inoculated with 100 μL of the bioluminescent E. coli. Control for bacterial growth without 
antibiotic were also included. The MIC was defined as the lowest concentration that showed no 
growth in the Mueller Hinton broth. Three independent experiments were done. 
 
2.3.7. Kill curves with phage and ciprofloxacin in Tryptic Soy Broth (TSB) 
Bioluminescent E. coli inactivation was determined using the phage and ciprofloxacin at 
MIC, 2xMIC, 1/5 MIC and 1/10 MIC, at a MOIs of 1 and 100 in TSB. In order to obtain a MOI of 1 
and 100, 6.5 µL of 108 URLs of the overnight bioluminescent E. coli culture (final concentration of 
105 URLs) and 12 µL for MOI of 1 and 300 µL for MOI of 100, of 108 PFU/mL of the phage 
suspension (final concentration of 105 and 107 PFU/mL, respectively) were inoculated in sterilized 
glass erlenmeyers with 30 mL of TSB and incubated at 25 °C at 50 rpm stirring (B+P). When the 
assays were performed with ciprofloxacin (B+P+Cip), the the same phage and bacteria 
concentrations were used. For these assays, three control samples were included: the bacterial 
control (BC), the phage control (PC) and antibiotic control (CipC). The bacterial control was 
inoculated with bioluminescent E. coli but not with phage, the phage control was inoculated with 
phage and without bacteria and the antibiotic control was inoculated with the bioluminescent E. 
coli and antibiotic. The controls and test samples were incubated exactly in the same conditions. 
Aliquots of test sample and bacterial and phage controls were collected at time zero and after 6, 
12, 18, 24 and 36 h of incubation for bioluminescence signal measurement (BC, B+P, CipC, 
B+P+Cip) and phage quantification (PC, B+P, B+P+Cip). The bioluminescence signal was measured 
in the luminometer (TD-20/20 Luminometer, Turner Designs, Inc., Madison, WI, USA) in triplicate. 
The phage titer was determined, in duplicate, through the double agar layer method and plates 
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were incubated for 12 h at 25 °C and expressed in PFU/mL. Three independent experiments were 
performed. 
 
2.3.8. kill curves with different ciprofloxacin addition times  
E. coli inactivation was determined using phage and ciprofloxacin at MIC and at MOI of 100 
in TSB. The bacterial and phage suspension was inoculated as described (see section 2.3.7), with a 
final concentration of 105 CFU/mL and 107 PFU/mL, respectively. When the assays were 
performed with ciprofloxacin (B+P+Cip), the concentrations of phage and bacteria described 
above (see section 2.3.7) were used. The ciprofloxacin was added at time zero and 6, 12 or 18 h of 
incubation. Three control samples were included: the bacterial control (BC), the phage control 
(PC) and antibiotic control (CipC). The bacteria control, phage control, antibiotic control and test 
samples were prepared as described above (see section 2.3.7). All controls were incubated exactly 
in the same conditions as the test samples. Aliquots of test samples, bacterial and phage control 
were collected at time zero and after 6, 12, 18, 24 and 36 h of incubation. The phage titer and 
bioluminescence signal were determined as described above (see section 2.3.7). Three 
independent experiments were performed.  
 
2.3.9. Determination of the rate of emergence of bacterial mutants 
The development of resistant mutants of E. coli to phages, to ciprofloxacin at 1/5 MIC and 
MIC, to phage and ciprofloxacin at 1/5 MIC and MIC was evaluated. To determinate the frequency 
of phage-resistant bacteria, ten isolated colonies from a plate with sensitive bacteria were 
selected and inoculated into ten tubes with 5 mL of TSB, grown at 25 °C for 18 h. The previously 
prepared ten TSB cultures of bacteria were also used to determine the development of phage-
resistant bacteria in the presence of ciprofloxacin. To determine the phage resistant mutants, 
aliquots of 100 µL from the 100 to10−2 dilutions of the bacterial culture aliquots of 100 µL of the 
phage from a stock solution of 109 PFU/mL were inoculated in tubes with TSB 0.6%, plated on TSA 
plates and incubated at 25 °C for 48 h (because some of the phage-resistant mutants grow very 
slowly). Simultaneously, 100 µL aliquots of 10−5 to 10−7 dilutions of the bacterial culture were 
plated by incorporation on TSA plates without phage or without phage and antibiotic, and 
incubated at 25 °C for 24 h. The previous prepared ten TSB cultures of bacteria were also used to 
determine the phage-resistant mutants in the presence of ciprofloxacin. The same procedure was 
used, but the cultures were added of antibiotic. To determinate the frequency of E. coli mutants 
resistant to the antibiotic (without phage), aliquots of 100 µL from the 10-1 to 10−5 dilutions of the 
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bacterial culture were plated on TSA plates and incubated at 25 °C for 48 h. To determinate the 
frequency of E. coli mutants resistant to the antibiotic (with phage) aliquots of 100 µL from the 
100 to 10−2 dilutions of the bacterial culture were plated on TSA plates by double agar layer 
method and incubated at 25 °C for 48 h. The calculation of the frequency of mutants was done by 
dividing the number of resistant bacteria (obtained from the ten isolated colonies) by the total 
number of sensitive bacteria. This formula was used to calculate the frequency of antibiotic 
resistant mutants, phage resistant mutants and the frequency of mutants for the mixture of 
phage and antibiotic. 
 
2.3.10. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 7.04. Normal distributions were 
assessed by Kolmogorov-Smirnov test and homogeneity of variances were assessed by Levene's 
test. A value of p < 0.05 was considered statistically significant and in these cases Tukey's multiple 
comparison test was used for a pairwise comparison of the means. The existence of significant 
differences on bacterial concentration in killing curves assays was analyzed using a two-way 
ANOVA with repeated measures. The significance of the differences was evaluated by comparing 
the results obtained in the test samples and control samples for the different times between 
treatments of each of the three independent assays, along different time. One-way ANOVA was 
used to examine differences between the concentration of resistant bacteria in presence of the 
antibiotics, in the presence of the phage alone and in presence of both simultaneously. 
 
2.4. Results 
2.4.1. Phage Host Range and Efficiency of Plating (EOP) Analysis 
Spot tests indicated that phage had the capacity to form completely cleared zones on 5 (E. 
coli bioluminescent, E. coli BC30, E. coli ATCC 25922, S. Typhimurium ATCC 13311 and S. 
Enteriditis CVD) of the 32 strains (Table 2.1). However, EOP results indicated that the phage 
formed phage lysis plaques in only 2 strains (E. coli ATCC 25922 and S. Typhimurium ATCC 13311) 
of the 32 strains tested. Phage infected E. coli ATCC 25922 and S. Typhimurium ATCC 13311 with 
an efficacy of 2.27 x 103 and 3.45 x 10-3, respectively (Table 2.1). 
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Table 2.1: Host range and efficiency of plating of E. coli phage determined on 32 bacterial strains. Clear lysis 
zone (+) and not lysis zone (-). 
Species Infectivity 
of phage 
Efficacy of plating 
(%) 
Escherichia coli bioluminescent (host) + 100 
Escherichia coli AE11 - 0 
Escherichia coli AN19 - 0 
Escherichia coli AD6 - 0 
Escherichia coli AF15 - 0 
Escherichia coli BC30 + 0 
Escherichia coli AC5 - 0 
Escherichia coli AJ23 - 0 
Escherichia coli BN65 - 0 
Escherichia coli BM62 - 0 
Escherichia coli ATCC 25922 + 2.27 x 103 
Escherichia coli ATCC 13706 - 0 
Enterobacter cloacae - 0 
Citrobacter freundii 6F - 0 
Proteus mirabilis - 0 
Providencia sp. - 0 
Salmonella Typhimurium ATCC 13311 + 3.45 x 10-3 
Salmonella Enteriditis CVA - 0 
Salmonella Enteriditis CVB - 0 
Salmonella Enteriditis CVC - 0 
Salmonella Enteriditis CVD + 0 
Salmonella Enteriditis CVE - 0 
Salmonella Typhimurium ATCC 14028 - 0 
Shigella flexneri DSM 4782 - 0 
Vibrio parahaemolyticus DSM 27657 - 0 
Vibrio anguillarum DSM 21597 - 0 
Aeromonas salmonicida CECT 894 - 0 
Aeromonas hydrophilla ATCC 7966 - 0 
Listeria innocua NCTC 11288 - 0 
Listeria monocytogenes NCTC 1194 - 0 
Photobacterium damselae damselae DSM 7482 - 0 
Pseudomonas aeruginosa - 0 
 
2.4.2. Determination of Minimum inhibitory concentration (MIC)  
The assessed MIC of the bioluminescent E. coli to ciprofloxacin was 0.25 mg/L. 
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2.4.3. Correlation between bioluminescence and CFU  
A linear correlation between viable counts and the bioluminescence signal of overnight 
cultures of the bioluminescent E. coli was observed (Figure 2.1). 
 
 
Figure 2.1: Association between the bioluminescence signal and viable counts of an overnight culture of a 
transformed bioluminescent E. coli. Bioluminescence is expressed in RLUs and viable counts in CFU/mL. 
 
2.4.4 Kill curves with phage and ciprofloxacin in TSB 
The results of the experiments show that the phage Ec-Bio was able to cause a decrease in the 
bioluminescence signal (ANOVA, p < 0.05) after 12 h of phage treatment (B+P), relatively to the 
bacterial control (BC) (Figure 2.2 AI-DI). The profile of variation was similar for both MOI (by 2.5 
log units for MOI of 1 and 2.8 log units after 12 h for MOI of 100). However, after this period, E. 
coli regrowth was observed, reaching values similar (ANOVA, p > 0.05) to that obtained in 
bacterial control after 36 h of incubation (Figure 2.2 AI-DI). 
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Figure 2.2: Effect of phage alone (MOI of 1) and combined phage and ciprofloxacin treatments. at different 
concentrations (A - 1/10 of MIC, B - 1/5 of MIC, C – MIC and D - 2x of MIC) on the inactivation of 
bioluminescent E. coli (I) and the phage concentration (II) in TSB during 36 h. BC – bacterial control, PC – 
Phage control, B+P – bacteria plus phage, CipC – bacteria plus ciprofloxacin, B+P+Cip – bacteria plus phage 
plus antibiotic. Values represent the mean of three independent experiments. 
 
When the phage was combined with antibiotic at a sublethal concentrations (1/10 and 1/5 
of MIC) at both MOIs, the E. coli inactivation was similar in both MOIs (ANOVA, p> 0.05) (Figure 
2.2AI and BI and Figure 2.3AI and BI). The maximum rate of bacterial inactivation when phage was 
combined with ciprofloxacin at 1/10 (B+P+Cip1/10MIC) and 1/5 of MIC (B+P+Cip1/5MIC), 
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relatively to the bacterial control, was ~2.7 and 2.4 log RLU, respectively, achieved after 12 h of 
treatment (Figure 2.3AI and 2.3BI). However, after 36 h of incubation for the both sublethal 
concentrations and for both MOIs, E. coli regrowth was observed, reaching bacterial densities 
similar (ANOVA, p > 0.05) to that obtained in bacterial control after 36 h of incubation (Figure 
2.2AI and BI and Figure 2.3AI and BI). For this treatment, significant differences (ANOVA, p < 0.05) 
relatively to the treatment with antibiotic alone (CipC1/10MIC and CipC1/5MIC) were observed 
during 36 h of incubation. The bacterial inactivation in the treatment with antibiotic (CipC1/10MIC 
and CipC1/5MIC) was significantly lower than that observed in the treatment with phage, with or 
without the antibiotic (ANOVA, p < 0.05). The bacterial inactivation in the treatment with phage 
and antibiotic (B+P+Cip1/10MIC and B+P+Cip1/5MIC) was significantly higher (ANOVA, p < 0.05) 
than that observed when the phage was used alone (B+P) after 24 and 36 h of incubation. No 
decrease in bacterial inactivation was observed for the treatment with ciprofloxacin at these two 
sublethal concentrations (B+P+Cip1/5MIC and B+P+Cip1/10MIC) when compared with the 
bacterial control (BC).  
When the phage was combined with ciprofloxacin at lethal concentrations, MIC (B+P+CipMIC) 
and at 2xMIC (B+P+Cip2xMIC), the increase in the MOI from 1 to 100 promoted a decrease in E. 
coli bioluminescence after 12, 18 and 24 h of incubation (Figure 2.2CI and 2.2DI and 2.3CII and 2.3 
DII, ANOVA, p < 0.05), but the pattern of variation between treatments was similar (ANOVA, p > 
0.05) for both MOIs.  
The maximum rate of bacterial inactivation for the mix of the phage and ciprofloxacin at MIC 
(B+P+CipMIC) was ~2.5 log RLU achieved after 18 h of treatment at MOI of 100. In this treatment, 
as well as in the treatment with the antibiotic alone (CipCMIC), no regrowth of bacteria was 
observed until the end of the treatment (Figure 2.2CI and 2.3CII). When the phage was used 
alone, a significant regrowth, after 12 h of incubation, was observed (ANOVA, p < 0.05). 
The maximum rate of E. coli inactivation when the phage was combined with ciprofloxacin at 
2xMIC (B+P+Cip2xMIC), relatively to bacteria control, was ~2.7 log RLU (Figure 2.2DII, ANOVA, p < 
0.05), achieved after 18 h at MOI of 100, which was similar to that obtained in antibiotic control 
(Cip2xMIC). For this treatment, no significant differences (ANOVA, p > 0.05) relatively to the 
treatment with antibiotic alone (CipC2xMIC) were observed during 36 h of incubation (Figure 
2.2DI and 2.3DII). However, the bacterial inactivation in the treatment with antibiotic, with or 
without the phage, was significantly higher than that observed when the phage was used alone 
(ANOVA, p < 0.05). When the phage was combined with antibiotic at 2xMIC (B+P+Cip2xMIC) or 
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the antibiotic was used alone (CipC2xMIC), no regrowth of bacteria was observed until the end of 
the treatment.  
 
Figure 2.3: Effect of phage alone (MOI of 100) and combined phage and ciprofloxacin treatments. at 
different concentrations (A - 1/10 of MIC, B - 1/5 of MIC, C – MIC and D - 2x of MIC) on the inactivation of 
bioluminescent E. coli (I) and the phage concentration (II) in TSB during 36 h. BC – bacterial control,PC – 
Phage control,  B+P – bacteria plus phage, CipC – bacteria plus ciprofloxacin, B+P+Cip – bacteria plus phage 
plus antibiotic. Values represent the mean of three independent experiments. 
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For both MOIs, the phage control (PC) remained constant throughout the experiment 
(ANOVA, p > 0.05), but when the phage was incubated in the presence of the host without 
antibiotic, a significant increase (~3.4 log PFU/mL for MOI of 1 and ~1.8 log PFU/mL for MOI of 
100, ANOVA, p < 0.05) was observed (ANOVA, p < 0.05) (Figure 2.2 and 2.3). 
When the phage was incubated in the presence of the host and antibiotic at sublethal 
concentrations, the phage concentration was significantly higher (ANOVA, p < 0.05) than those 
observed in the phage control (PC) (Figure 2.2 AII and BII and 2.3AII and2.2BII). Increases of ~ 2.0 
and 0.5 log PFU/mL, respectively for MOIs of 1 and 100 with ciprofloxacin at 1/10, and increases 
of  ~ 2.0 and 1 log PFU/mL, respectively, for MOIs 1 and 100 with ciprofloxacin at 1/5,  however, 
for both MOIs, when the phage was incubated in the presence of the host and ciprofloxacin at 
lethal concentration, MIC (B+P+CipMIC) and 2xMIC (B+P+Cip2xMIC), the phage concentration 
remained constant (ANOVA, p > 0.05) throughout the experiment (Figure 2.2 CI and DI and 2.3CII 
and DII). In these cases, the phage concentrations were similar to that of the phage control (PC) 
(ANOVA, p > 0.05). 
 
2.4.5. Influence of time of addition of ciprofloxacin on the kill curves 
The rate of bacterial inactivation when the antibiotic was added after 6 h of phage addition 
was 2.3 log RLU relatively to the bacteria control, which was significantly higher (ANOVA, p < 0.05) 
than those obtained in the other conditions tested (B+P, B+P+Cip0h, B+P+Cip12h and 
B+P+Cip18h) after 36 h of incubation (Figure 2.4 AI, BI and CI). When the antibiotic was added 
after 6 h of phage addition, no regrowth of bacteria was observed until the end of the treatment, 
contrarily to those observed for the other two conditions. 
When the antibiotic was added after 12 h of phage addition, the bacterial inactivation, after 
36 h of incubation, decrease ~1.9 log RLU relatively to the bacteria control and was similar 
(ANOVA, p > 0.05) to that obtained when the antibiotic was added same time of the phage 
(decrease ~2.1 log RLU, relatively to the bacteria control). However, the bacterial inactivation in 
this treatment was significantly higher (ANOVA, p < 0.05) than those obtained in treatment with 
phage without antibiotic (bacteria concentration was similar to the bacteria control) (Figure 2.4 
AI, BI and CI). 
When the antibiotic was added after 18 h of phage addition, after 36 h of treatment, the 
bacterial density was similar (ANOVA, p > 0.05) to that obtained in bacteria control (BC) and to 
that obtained in the treatment with phage without antibiotic (B+P) (Figure 2.4 CI). In this 
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condition, until 18 h of incubation, bacterial inactivation was yet similar to that obtained in B+P 
(ANOVA, p > 0.05) (Figure 2.4 CI).  
 
 
Figure 2.4: Effect of time of addition of ciprofloxacin at MIC on the inactivation of bioluminescent E. coli (I) 
and the phage concentration (II) in TSB during 36 h. A - Antibiotic added after 6 h of phage addition, B - 
Antibiotic added after 12 h of phage addition, C - Antibiotic added after 18 h of phage addition. BC – 
Bacterial control, PC – Phage control, B+P – Bacteria plus phage, CipC0h – Bacteria plus antibiotic added at 
the same time of the phage, B+P+Cip0h – Bacteria plus phage plus antibiotic added at the same time of the 
phage, B+P+Cip6h – Bacteria plus phage plus antibiotic added at 6 h of phage addition, B+P+Cip12h – 
Bacteria plus phage plus antibiotic added at 12 h of phage addition, B+P+Cip18h – Bacteria plus phage plus 
antibiotic added at 18 h of phage addition. Values represent the mean of three independent experiments. 
 
While the phage control (PC) remained constant throughout the experiment (ANOVA, p > 
0.05) (Figure 2.4AII, BII and CII), when the bacteria were incubated in presence of the phage 
without antibiotic (B+P), a significant increase (increase ~1.8 log PFU/mL, ANOVA, p < 0.05) was 
observed (Figure 2.4AII, BII and CII).  
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When the bacteria were treated with the phage in the presence of the ciprofloxacin added 
6, 12 and 18 h after phage addition (B+P+Cip6h B+P+Cip12h and B+P+Cip18h), a significant 
increase was observed in the phage concentration (increase ~1.7 - 2.0 log PFU/mL, ANOVA, p < 
0.05). The number of produced phages in the three conditions (B+P+Cip6h B+P+Cip12h and 
B+P+Cip18h) was similar (ANOVA, p > 0.05) to that obtained without the antibiotic addition (B+P) 
and significantly higher than that observed when the antibiotic was added at the same time of the 
phage (increase ~0.5 log PFU/mL, relatively phage control) (Figure 2.4AII, BII and CII).  
 
2.4.6 Determination of the rate of emergence of bacterial mutants 
The bioluminescent E. coli showed different rates of resistant mutants emergence when 
subjected to ciprofloxacin alone, phage alone, and to the mix of the phage plus ciprofloxacin 
(Table 2.2). The development of resistant mutants of E. coli against the ciprofloxacin at 1/5 MIC 
and at MIC was significantly higher (ANOVA, p < 0.05) than that obtained when phage was used 
alone and when the mixture of phage and ciprofloxacin was used. However, the frequency of 
resistant mutants of E. coli in the presence of the phage alone was similar (ANOVA, p > 0.05) to 
that obtained when the phage was used in combination with ciprofloxacin at 1/5 MIC, but was 
significantly higher than that obtained when the phage was used in combination with the 
ciprofloxacin at MIC (ANOVA, p < 0.05). 
 
Table 2.2: Frequency of transformed E. coli spontaneous phage-resistant mutants. 
Sample 
Frequency of 
antibiotic-mutants 
(CFU/mL) 
Sample 
Frequency of 
phage and 
antibiotic mutants 
(CFU/mL) 
Sample 
Frequency of 
phage-mutants 
(CFU/mL) 
Cip MIC 
(0.25 
µg/mL) 
3.95 x 10-6 
Phage + 
Cip MIC 
4.04 x 10-7 
Phage 3.43 x 10-5 
Cip 1/5MIC 
(0.05 
µg/mL) 
5.24 x 10-1 
Phage + 
Cip 
1/5MIC  
4.00 x 10-5 
 
 
2.5. Discussion 
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With the emergence of antibiotic resistance in common bacteria, such as E. coli, even in 
commensal strains, there is a need to develop alternative treatments. Several studies have 
demonstrated that phages can be used to control pathogenic bacteria (Fu et al., 2010; Rivas et al., 
2010; Vieira et al., 2012; Maura and Debarbieux, 2012; Lood et al., 2015; Scanlan et al., 2015; 
Verstappen et al., 2016; Pereira et al., 2016a, 2016c, 2017a, 2017b), but the development of 
phage-resistant mutants is a general shortcoming (Bikard and Marraffini, 2012; Seed et al., 2014; 
Pereira et al., 2016a, 2017b). The combination of phage treatment with antibiotics is a possibility 
to avoid the emergence of resistance, but little is known about the interaction process of phages 
and antibiotics in combined therapies, particularly in regard to the emergence of phage-resistant 
mutants. In a previous work of our group (Valério et al., 2017), we demonstrated that the phage 
and antibiotic combinations could result in high synergistic effects in the inactivation of bacteria, 
but nevertheless bacterial regrowth after treatment was observed. So, in the present study, we 
try to understand if development of bacterial regrowth can be circumvented by the use of 
different antibiotic and phage concentration combinations and also by the application of the 
antibiotic after different times after phage addition. We showed that 1) phage and antibiotic 
combinations could result in positive effects in the inactivation of bacteria, preventing bacterial 
regrowth, but 2) the efficacy of the combination depends greatly on the concentration of 
antibiotic and on the time of antibiotic addition 3) not being much influenced by the phage 
concentration added at the beginning of the treatment (the MOI), 4) controlling effectively the 
development of bacterial resistance not only against antibiotics, but also against phages. 
The kinetic theory indicates that the MOI could be critical to the bacterial inactivation 
efficiency (Cairns et al., 2009). Several studies demonstrated, that the reduction of pathogenic 
bacteria increases in parallel with MOI or that bacterial reduction occurs sooner at higher MOI 
values (ChiHsin et al., 2000; Pasharawipas et al., 2011; Prasad et al., 2011). However, Nakai (2010) 
related that the initial doses of phage may not be essential, because due to its self-perpetuating 
nature, revealed by an increasing of phage titers along with bacteria. In this study, in general, the 
increase in MOI from 1 to 100 not promoted a significant increase in the efficiency of phage 
alone. Nevertheless, when phage was combined with ciprofloxacin at lethal concentrations, at 
MIC and 2xMIC, the increase of the MOI caused a decrease in bacterial density. This can be 
explained by the fact that in the presence of the antibiotic at high concentrations, host DNA 
replication inhibition avoids phage replication by the bacteria. If inhibition reduces the per-host 
cell output of phage, then overall phage titer may not be sufficient to cause massive reductions in 
bacterial cell density when the phage is added at low MOI 1. At MOI 100, even if the host DNA 
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replication is affected, the high number of phages already present at the beginning of the 
treatment is enough to more efficiently inactivate the bacteria. Contrarily, when the antibiotic 
was not added, the treatment with low MOI was enough to inactivate efficiently the bacteria 
because the host during the first hours of treatment replicates efficiently the phages, which after 
allows their inactivation by the new produced phages. In fact, the number of phages after 6 h of 
treatment at MOI of 1 increased more (by 3.4 log PFU/mL in B+P sample) than at MOI 100 
(increase by 1.8 log PFU/mL). This confirms the hypothesis that due to the self-perpetuating 
nature of phages, precise initial doses of phage may not be essential. This is one of the major 
advantages of phage treatment in relation to antibiotics. On the other hand, too high MOI can be 
a disadvantage for the success of phage treatment because the bacteria can be inactivated before 
replicating the phages, which is known as “lysis from without”, due to a high concentration of 
phage lytic enzymes (Kao and McClain, 1980; Arisaka et al., 2003; Nakai, 2010; Brown and Bidle, 
2014), not allowing to reach an enough number of phages to inactivate the no enzyme lysed 
bacteria. 
Although antibiotics can affect the phage production by the host bacteria (Valério et al., 
2017), some studies have demonstrated improved efficacy of associating phages and antibiotics 
to control pathogenic bacteria (Kirby, 2012; Ryan et al., 2012; Chhibber et al., 2013; Knezevic et 
al., 2013; Coulter et al., 2014; Torres-Barceló et al., 2014; Valério et al., 2017), preventing even 
the bacterial regrowth (Kirby, 2012; Knezevic et al., 2013; Torres-Barceló et al., 2014; Valério et 
al., 2017). As the combination of phages and antibiotics attack different bacterial targets, the 
probability of bacterial regrowth, due to the emergence of resistant mutants to both agents, is 
reduced (Escobar-Páramo et al., 2012; Hall et al., 2012). 
The results of present study indicate that the combined treatment with antibiotic at 
sublethal and lethal concentrations when added at the same time of the phages, do not increase 
the efficacy of bacterial inactivation relatively to the treatment with phages alone, but effectively 
prevent the emergence of bacterial regrowth when used at MIC or at a concentration two times 
higher the MIC.  
An increase in bacterial inactivation was not observed for the combined therapy when the 
ciprofloxacin was used at a sublethal concentration (1/10 and 1/5 of MIC). However, the 
combination with the antibiotic at 1/5 of MIC delayed the development of resistant bacteria. 
When the antibiotic was added at 1/5 of MIC, the regrowth of bacteria was observed later than in 
the sample treated with phages and antibiotic, after 24 h against 12 h for the treatment with the 
phage alone. When phage was combined with ciprofloxacin at lethal concentrations, MIC and 
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2xMIC, after 12 h of treatment, when the maximum of bacterial inactivation was observed, 
bacterial density reduction by the combined therapy (B+P+CipMIC and B+P+Cip2xMIC) was lower 
than that caused by the phage alone (B+P), but was higher than that obtained with ciprofloxacin 
alone (CipC). However, when phage was combined with ciprofloxacin at 2xMIC, the difference 
observed between treatment with the combination phage and antibiotic and with the antibiotic 
alone was not so high than that observed when the antibiotic was used at MIC. Nevertheless, the 
combined treatment with these high antibiotic concentrations effectively prevented the 
development of resistant bacteria. When the combined treatment with antibiotic at lethal 
concentrations was added, no regrowth of bacteria was observed until the end of the treatment, 
as observed for the antibiotic alone at both concentrations, but contrarily to that observed when 
phages were used alone (regrowth after 12 h). 
In this study it was clear that the addition of the antibiotic alone or in the presence of the 
phages affects the phage production by the bacteria according to the used concentration, but, 
even in these situations, the concentration of phages does not seem to be a limiting factor for 
bacterial inactivation. In combined treatments with ciprofloxacin at sublethal concentrations 
(B+P+Cip1/10MIC and B+P+Cip1/5MIC), the number of phages in the presence of the host 
increased significantly (~2.0 and ~0.5 -1.0 log PFU/mL, respectively), but in treatment with 
ciprofloxacin at MIC and 2xMIC remained constant (phage concentration similar to that of phage 
control). This can be explained by the fact that as the phage and antibiotic are applied 
simultaneously, antibiotic is likely to constrain the phage replication by the bacteria by means of 
nucleic acid synthesis inhibition, increasing this constraining with the increase of antibiotic 
concentration. The ciprofloxacin inhibits the enzymes topoisomerase II (DNA gyrase) of the host, 
affecting its nucleic acid synthesis, and, consequently, interfering with the replication of the 
phage by the host bacteria (Wishart et al., 2006). Although the antibiotic addition avoids phage 
replication by the bacteria, namely when used at high concentrations, the number of phage 
added at the beginning of the treatment was enough to allow the bacterial inactivation. However, 
the bacterial inactivation in these conditions is delayed relatively to the treatment with the phage 
alone or with the combined treatment with sublethal antibiotic concentrations. 
Taking into account the results obtained in these experiments, the next step was to 
evaluate the efficacy of bacterial inactivation using the combined treatment but adding the 
antibiotic after phage addition. The results of the previous experiments indicate that efficiency of 
the combined therapy with antibiotics and phages depend on the ability of the host bacteria to 
replicate the phages, which is affected by the antibiotic concentration. Similar results were 
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already obtained in other studies (Levin and Bull, 1996; Ryan et al., 2011). So, in these 
experiments, antibiotic at MIC was added after, 6, 12 and 18 h of phage addition. 
The E. coli was most effectively inactivated when the antibiotic was added after the phage 
for the three tested times, but the prevention of bacterial regrowth was more effective when the 
antibiotic was added after 6 h of phage addition. The antibiotic addition after 12 h of the phage 
was also effective to prevent the bacterial regrowth but not as effective as observed after 6 h. The 
antibiotic addition after 18 h of phage addition was not effective to prevent bacterial regrowth. 
Using this sequential approach to add the phage and antibiotic in combined treatment allows the 
bacteria to replicate the phages efficiently. The number of produced phages in the three 
conditions was similar to that obtained without the antibiotic addition (increase of around 2 log in 
both conditions) and significantly higher than that observed when the antibiotic was added at the 
same time of the phage (maximum increase of around 0.5 log). Overall, these results indicate that 
the combined treatment with antibiotic added after 6 h of phage addition is the best option to 
prevent bacterial regrowth. Torres-Barceló et al. (2014) obtained similar results for Pseudomonas 
aeruginosa using the combination of phage LUZ7 and the antibiotic streptomycin when the 
antibiotic was added after 12 h of phage addition. 
The results of this study showed that the combination of antibiotics with phages is an 
effective alternative to prevent bacterial regrowth, controlling the emergence of resistance to the 
phages but also to the antibiotic. Similar results have been obtained by other authors (Kirby, 
2012; Coulter et al., 2014; Torres-Barceló et al., 2014, 2016; Viertel et al., 2014; Oechslin et al., 
2017; Valério et al., 2017), but few of these studies discriminate between prevention of resistance 
to phages and resistance to antibiotics resulting from the combined treatment (Torres-Barceló et 
al., 2014, 2016; Valério et al., 2017). 
In this study, we compared not only the resistance of the bacteria to the combined 
treatment with phages and ciprofloxacin at MIC and at a subinhibitory concentration (1/5 MIC), 
but also the resistance to the phages alone and to the antibiotic alone. The results of this study, as 
indicated by some other authors (Verma et al., 2009; Zhang and Buckling, 2012; Valério et al., 
2017), showed that the combined treatment limits the emergence of antibiotic resistant variants. 
The overall rate of emergence of resistant bacteria was significantly lower in the combined 
treatment (4.0 x 10-7 and 4.0 x 10-5) than that observed when only the antibiotic (3.95 x 10-6 and 
5.24 x 10-1) were used, for both conditions, ciprofloxacin at MIC and at 1/5 MIC. However, when 
the ciprofloxacin was tested at the subinhibitory concentration, the overall rate of bacterial 
emergence and the rate of emergence of antibiotic mutants was significantly higher. Contrarily, 
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other studies demonstrated that phage-antibiotic combinations cause the same resistance than 
phage and antibiotic introduced individually (Verma et al., 2009; Zhang and Buckling, 2012; 
Torres-Barceló et al., 2014). However, to the best of our knowledge, no study indicated that 
resistance to antibiotics in combined treatment was higher than that developed without phages.  
In this study, the emergence of phage-resistant mutants was also determined. When 
ciprofloxacin was added at a MIC together with the phage, the frequency of emergence of phage-
mutants was lower (4.0 x 10-7) than that observed when the antibiotic was not added (3.43 x 10-5). 
However, this reduction was not detected for ciprofloxacin at subinhibitory concentration (1/5 of 
MIC). In this case, the resistance of phage-mutants in the presence of ciprofloxacin was similar to 
that when phages were tested alone. However, in our previous study (Valério et al., 2017), using 
other phage of E. coli, the addition of ciprofloxacin at subinhibitory concentration (1/10 MIC), 
during phage treatment reduced the emergence of phage-mutants. Further studies, using 
different antibiotic concentrations and different bacteria and phages, are necessary to clarify the 
reason for this different behavior. 
 
2.6. Conclusion 
In conclusion, we can state that combined treatment with phages and antibiotics is 
effective in reducing the bacterial density, but also to prevent the emergence of resistant 
variants. However, the antibiotic concentration and the time of antibiotic application are essential 
factors to be considered in the combined treatment. In the case of the E. coli stains used in this 
study, the combined therapy with the phage Ec-Bio and the antibiotic ciprofloxacin, the efficiency 
of inactivation and the prevention of resistant mutants is higher when the antibiotic is used at 
MIC and added after 6 h of phage addition. The combined treatment can be used to inactivate E. 
coli, including antibiotic resistant strains, which are among the main responsible for moderate and 
serious infections in the hospital and community environments. 
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Abstract 
A major source of financial loss for the fish-farming industry is the occurrence of bacterial 
infections. Phage therapy can be a useful alternative tool to conventional treatments to control 
bacterial infections in aquaculture. The promising results obtained with phage AS-A to control the 
agent of furunculosis, Aeromonas salmonicida, led us to isolate two new phages and evaluate 
their dynamics, in cocktails and individually, to control this pathogenic bacterium. Moreover, 
considering that in outdoor facilities aquaculture water is exposed to the natural variability of 
physical and chemical parameters, the influence of pH, salinity, temperature, solar radiation and 
UV radiation on phage AS-D stability was also evaluated in this study, in order to develop an 
effective phage therapy protocol. Phages were assigned to the family Myoviridae and revealed 
identical morphological characteristics. Phage AS-A presents a higher burst size and a shorter 
latent period, decreasing the concentration of A. salmonicida sooner than phages AS-D and AS-E. 
However, phage AS-D presented higher rate of bacterial reduction, inducing also less bacterial 
resistance. Bacterial control with the cocktails was higher, namely when phage AS-A was 
combined with one of the two new phages or with both, but the main difference in the bacterial 
control was in the treatment time. Phage cocktails decrease the concentration of A. salmonicida 
sooner than single suspensions. The use of phage cocktails, in general, decreased phage-resistant 
mutants. The survival of ASD phage was mostly affected by sunlight exposure (decrease of 3 log 
PFU/mL after 12 h) and high temperatures (decrease of 3 PFU/mL after 21 days and of 7 log 
PFU/mL after 49 days at 37 °C, but no decrease after 21 and 49 days at 25 °C and decrease of only 
1 and 2 log PFU/mL after 21 and 49 days, respectively, at ambient temperature). The high 
bacterial control and low development of phage-resistant bacterial clones suggest that these 
phages can be used to control the furunculosis in aquaculture. Nonetheless, the stability of the 
phages was affected by solar radiation, this can be overcome by the application of phages at the 
end of the day or at night. 
 
Keywords: Phage treatment, phage cocktails, fish pathogenic bacteria, multidrug resistance 
bacteria, physico-chemical factors 
 
3.1. Introduction 
Fisheries and aquaculture remain important sources of food, nutrition, income and 
livelihoods for hundreds of millions of people around the world (FAO, 2016). World aquaculture 
production of fish accounted for 44.1% of total production from capture fisheries and aquaculture 
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in 2014, up from 42.1% in 2012 and 31.1% in 2004 (FAO, 2016). World aquaculture combined 
production of fish and plants reached 101.1 million tons in live weight in 2014, for an estimated 
total farm gate value of US$165.8 billion (FAO, 2016). However, aquaculture industries frequently 
suffer heavy financial losses that threaten their growth and sustainability, due mainly to 
uncontrolled microbial diseases (Almeida et al., 2009). Aquaculture fish are subjected to greater 
stress than wild conspecifics, which contributes to a reduction of their natural immune system 
and often favors bacterial infections, namely during their early life stages (Shao, 2001; Wahli et 
al., 2002; Silva et al., 2016). This scenario can favor opportunistic infections and cause significant 
economic losses to producers.  
Aeromonas salmonicida, the causative causative agent of furunculosis and fish septicaemia, 
is a relevant pathogen in aquaculture, responsible for causing significant economic losses 
worldwide (González et al., 2004; Janda and Abbott, 2010; Noga, 2011; Diamanka et al., 2013; 
Dallaire-Dufresne et al., 2014; Tewari et al., 2014) due to high mortality and morbidity in a variety 
of fish species (e.g., salmon (Ringø et al., 2004; Verner–Jeffreys et al., 2007)), trout (Nikoskelainen 
et al., 2001; Imbeault et al., 2006), turbot (Farto et al., 2011; Lago et al., 2012; Coscelli et al., 
2014), Atlantic cod (Arnesen et al., 2010), rockfish (Kim et al., 2013), seabream (Zorrilla et al., 
2003) and wolffish (Grontvedt and Espelid, 2004)). The consequences of furunculosis are 
especially severe in farmed fish in the absence of vaccination (Bergh, 2008). Although efficient 
vaccines are available, they are still expensive and often associated with undesirable side effects 
(Midtlyng, 1997; Björnsdóttir et al., 2005; Cipriano and Austin, 2011). The regular use of artificial 
food supplemented with antibiotics in intensive and semi-intensive aquaculture system, to 
prevent the spread of diseases and their massive use to control infections, has resulted in the 
development of resistant strains, which have contributed to the inefficacy of antibiotic treatments 
(Martínez and Hipólito-Morales, 2013). The recent emergence of antibiotic resistant A. 
salmonicida strains in aquaculture has been observed (Reith et al., 2008; Kim et al., 2011), making 
alternative control methods to treat furunculosis urgently needed.  
Phage therapy is a proven eco-friendly alternative approach to prevent and control 
pathogenic bacteria in aquaculture (Nakai et al., 1999; Park et al., 2000; Nakai and Park, 2002; 
Park and Nakai, 2003; Vinod et al., 2006; Karunasagar et al., 2007; Higuera et al., 2013; Silva et al., 
2014b, 2016). The use of phages to prevent infection or to control different fish pathogenic 
bacteria is well documented (Nakai et al., 1999; Park and Nakai, 2003; Crothers-Stomps et al., 
2010; Silva et al., 2014b, 2016). A number of phages infecting Aeromonadaceae isolated from 
different environments around the world have already been characterized (Beilstein and 
    
81 
 
Dreiseikelmann, 2008; Kim et al., 2012a, 2012 b; Silva et al., 2016), and, in last years, A. 
salmonicida phages have been successfully used to treat furunculosis in brook trout (Salvelinusn 
fontinalis) (Imbeault et al., 2006), Atlantic salmon (Salmo salar) (Verner–Jeffreys et al., 2007), 
rainbow trout (Verner–Jeffreys et al., 2007) and Senegalese sole (Solea senegalensis) (Silva et al., 
2016). In one recent study of our group, it was showed the application of AS-A phage that 
inhibited the growth of A. salmonicida both in batch cultures and in Solea senegalensis juveniles 
(Silva et al., 2016). After 72 h, fish juveniles treated with AS-A phage after exposure to A. 
salmonicida showed no mortality, contrarily to juveniles that were only exposed to the bacterium, 
which presented a mortality of 36% (Silva et al., 2016). However, some bacteria after treatment 
developed resistance to phage AS-A, but the rate of resistance was, however, low (2.24×10−4). The 
development of phage-resistance can be overcame by the combined use of more than one phage 
at the same time, that can be achieved by the use of phage cocktails (Crothers-Stomps et al., 
2010; Chan et al., 2013; Mateus et al., 2014). A cocktail of several phages, each one virulent to the 
target bacterial strain but binding to different surface receptors, will make it very difficult for the 
bacteria to develop resistance. To the best of our knowledge, here is only one report about the 
use of phage cocktails to control the agent of the furunculosis (Verner–Jeffreys et al., 2007). In 
this study, juvenile fish were initially infected with A. salmonicida subsp. salmonicida and treated 
with a cocktail of 3 lytic phages. Fish treated with the phage cocktail lived longer but still died of 
furunculosis by the end of the study (within 96 h). The time until death was dependent on how 
long the phage was administered after injection of the bacterium. The fish that were treated with 
phages cocktail immediately after infection died more slowly than those that were either not 
treated with phages, or treated 24 h post-infection (Verner–Jeffreys et al., 2007). 
For an effective treatment in aquaculture, phages should be stable over time when exposed 
to the natural variability of physical and chemical parameters. Consequently, the effect of the 
physico-chemical factors in the stability and survival of phages should be taken into account. It is 
known that the stability of a virus can be negatively affected by various factors such as pH, 
salinity, UV-light and temperature (Jończyk et al., 2011; Maura and Debarbieux, 2011; Ly-Chatain, 
2014). For phage best activity, pH values should not be lower than 6 or higher than 8, salt must be 
at low concentrations and temperature should be near the optimal for each phage. UV radiation is 
considered the most important factor to be controlled, as it modifies genetic material, therefore 
killing the viruses (Jończyk et al., 2011; Maura and Debarbieux, 2011; Ly-Chatain, 2014). Some 
authors assume a connection between a phage morphology and its occurrence and infectivity in 
adverse environments, but evidence supportive of that hypothesis is lacking (Lasobra et al., 1997). 
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Under unfavorable environmental conditions, phage stability can be affected through damage of 
its structural elements (head, tail, envelope), lipid loss, and/or DNA structural changes 
(Ackermann et al., 2004). In general, bacteriophage stability is highly variable and sensitivity of 
individual phage classes is highly diversified (Jończyk et al., 2011). Pereira et al. (2011a) showed 
that the pattern of survival of phages infecting important aquaculture pathogenic bacteria is 
different in culture waters. An A. salmonicida phage survived in fish-farm water during 90 days. In 
contrast, the abundance of Vibrio parahaemolyticus phage strongly decreased during the 
incubation period, showing a survival time of 16 days (Pereira et al., 2011a). 
In our previous study, phage AS-A has demonstrated a remarkable efficacy in the control of 
A. salmonicida both in batch cultures and in juveniles of Senegalese sole (Silva et al., 2016), but 
some phage-resistant mutants emerged. So, in the present study, we extended our research to 
the isolation of new phages and we studied the efficiency of cocktails of two and three phages to 
control the emergence of resistant bacteria. Additionally, taking into account that in outdoor 
facilities, aquaculture water is exposed to natural variation of the environmental factors, and that 
the survival and persistence of phages are affected by physico-chemical factors, in this study the 
influence of pH, salinity, temperature, solar radiation and UV radiation on phage AS-D stability 
was also evaluated in order to develop an effective phage therapy protocol. 
 
3.2. Material and methods 
3.2.1. Bacterial strains and growth conditions 
The bacterial strains used in this study are listed in Table 1. A. salmonicida (CECT 894), 
Aeromonas hydrophilla (ATCC 7966), Vibrio fischeri (ATCC 49387), Salmonella enterica serovar 
Typhimurium (ATCC 13311 and ATCC 14028), Escherichia coli (ATCC 25922 and 13,706), Vibrio 
parahaemolyticus (DSM 27657), Vibrio anguillarum (DSM 21597) and Photobacterium damselae 
subsp. damselae (DSM 7482) were purchased from CECT, ATCC and DSM collection, respectively. 
The bacterial strains, Aeromonas sp. K15-2FS, Aeromonas salmonicida AH010906–3, Aeromonas 
salmonicida subsp. achromogenes AT4175 and Vibrio ordalii VI-30, used in this study were 
previously isolated in another laboratory. All other bacterial strains used in the present study 
were isolated in previous works from water samples collected in Ria de Aveiro (Louvado et al., 
2012; Silva et al., 2016; Pereira et al., 2016a, 2017b). Fresh plate cultures were maintained in 
Tryptic Soy Agar medium (TSA; Liofilchem, Italy) at 4 °C. Before each assay, one isolated colony 
was transferred to 10 mL of Tryptic Soy Broth medium (TSB; Liofilchem, Italy) and was grown 
overnight at 25 °C. An aliquot of this culture (100 μL) was transferred to 10 mL of fresh TSB 
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medium and grown overnight at 25 °C to reach an optical density (O.D. 600) of 0.8, corresponding 
to about 109 cells/mL. 
 
3.2.2. Phage isolation and purification 
The phage AS-A used in this study was previously isolated in our laboratory (Silva et al., 
2016) and the other two phages (AS-D and ASE) were isolated from sewage network of Aveiro 
(SIMRIA Multi Sanitation System of Ria de Aveiro - station EEIS9) collected at different times. 
Sewage water was filtered through 0.45 μm pore size polycarbonate membranes (Millipore, 
Bedford, MA, USA). The filtrate was added to double-concentrated TSB medium with 1 mL of 
fresh culture of the host, A. salmonicida CECT 894. The mixtures were incubated at 25 °C for 18 h 
at 80 rpm, and then filtered through a 0.2 μm membrane (Millipore Bedford, MA, USA). Plates 
were incubated at 25 °C and observed for the presence of lytic plaques after 12 h. One single 
plaque was removed from the agar and added to TSB medium with a fresh culture of the host. 
The sample was centrifuged, being the supernatant used as a phage source for a second isolation 
procedure. Three successive single-plaque isolation cycles were performed in order to obtain pure 
phage stocks. All lysates were centrifuged at 10.000 g for 10 min at 4 °C, to remove intact bacteria 
or bacterial debris. The phage stocks were kept at 4 °C. The phage suspension titers were 
determined by the double-layer agar method using TSA (TSA soft with 0.6% of agar in tubes and 
TSA with 1.5% of agar in plates) as culture medium (Adams, 1959). The plates were incubated at 
25 °C for 12 h and the number of lysis plaques was counted. The results were expressed as plaque 
forming units per milliliter (PFU/mL). 
 
3.2.3. Electron microscope examination 
Phage particles of a highly concentrated suspension (109 PFU/mL) were negatively stained 
with 2% uranyl acetate (Electron Microscopy Sciences, Hatfield, UK) and electron micrographs 
were taken using a JEOL 1011 transmission electron microscope (JEDL USA Inc., Peabody, MA, 
USA) operating at 100 kV and images were acquired with a Gatan CCD-Erlangshen ES100W. 
 
3.2.4. Phage host range and efficiency of plating (EOP) analysis 
Firstly, phage host range was determined by spot testing according to Adams (1959). The 
plates were incubated at 25 °C and examined for plaques after 12 h. Bacterial sensitivity to a 
phage was established by a lysis cleared zone at the spot. According to the clarity of the spot, 
bacteria were differentiated into two categories: clear lysis zone (+) and no lysis zone (−). The 
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efficiency of plating (EOP) was determined for bacteria with positive spot tests (occurrence of a 
clear lysis zone), using the double-layer agar method (Adams, 1959). The EOP was calculated 
(average PFU on target bacteria/average PFU on host bacteria) (Kutter, 2009) along with the 
standard deviation for the three measurements. For each phage, three independent experiments 
were done. 
 
3.2.5. One step growth assays 
Exponential host bacterial cultures of A. salmonicida were adjusted to a 0.8 O.D. at 600 nm 
(corresponding to a cell density of 109 CFU/mL). Ten microliters of the phage suspensions (final 
concentration: 106 PFU/mL) were added to 10 mL of the bacterial culture in order to have a MOI 
of 0.001 and incubated at 25 °C (Mateus et al., 2014). The mixture was centrifuged at 12.000 g for 
5 min, the pellet was resuspended in 10 mL of TSB at 25 °C and then it was diluted and titrated. 
The plates were incubated at 25 °C and examined for plaques after 4–8 h (Mateus et al., 2014). 
Three independent assays were done. 
 
3.2.6. Bacterial kill curves 
Phage therapy was performed using phages AS-D and AS-E individually and with phage 
cocktails (two or all the three phages mixed together, each phage at the same concentration) 
using the bacterium A. salmonicida as host, at a MOI of 100. In order to obtain a MOI of 100, 2.5 
μL of 109 CFU/mL of the overnight A. salmonicida culture (final concentration of 105 CFU/mL) and 
200 μL of 109 PFU/mL of the phage suspension (final concentration of 107 PFU/mL) were 
inoculated in sterilized glass erlenmeyers with 30 mL of TSB medium and incubated at 25 °C 
without agitation (B+P). The tested phage cocktails were: ASD/AS-E, AS-A/AS-D, AS-A/AS/E and 
AS-A/AS-D/AS-E phages. For each assay, two control samples were included: the bacterial control 
(BC) and the phage control (PC). The bacterial control was inoculated with A. salmonicida but not 
with phages and the phage controls were inoculated with phages but not with bacteria. Controls 
and test samples were incubated in the same conditions. Aliquots of test samples and of the 
bacterial and phage controls were collected after 0, 2, 4, 6, 8, 10 and 12 h of incubation. In all 
assays, the phage titre was determined in duplicate through the double agar layer method after 
an incubation period of 8–12 h at 25 °C. Bacterial concentration was determined in duplicate in 
TSA medium after an incubation period of 24 h at 25 °C. Three independent experiments were 
performed for each condition. 
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3.2.7. Determination of the rate of emergence of phage-resistant mutants 
In order to determinate the frequency of phage-resistant bacteria, ten isolated colonies 
from a plate with sensitive bacteria were selected and were inoculated into ten tubes with 5 mL 
of TSB medium, grown at 25 °C for 24 h (concentration around 109 CFU/mL). Aliquots of 0.1 mL 
from the 100 to 10−2 dilutions of the bacterial culture and aliquots of 0.1 mL of the phage from a 
stock solution of 109 PFU/mL were inoculated in tubes with TSA soft (MOI 1), plated on TSA and 
incubated at 25 °C for 3–5 days (because some of the phage-resistant mutants grow very slowly). 
Simultaneously, 0.1 mL aliquots of 10−5 to 10−7 dilutions of the bacterial culture were plated on 
TSA plates without phage and incubated at 25 °C for 24 h (Filippov et al., 2011). The calculation of 
the frequency of mutants was done by dividing the number of resistant bacteria (obtained from 
the ten isolated colonies) by the total number of sensitive bacteria (prepared from the culture 
without phages) (Filippov et al., 2011). Three independent assays were performed.  
 
3.2.8. Isolation of phage-resistant mutants 
Sensitive A. salmonicida (CECT 894) was grown at 25 °C during 16 h. A soft agar overlay 
seeded with 300 mL culture was then spotted with 10 mL of each of two lytic phage suspensions. 
Using high phage titers, clear zones where there was complete absence of visible bacterial growth 
were created. However, after 24 h of incubation, resistant colonies were observed in these zones. 
The phage resistant colonies were picked up and purified by successive sub-culturing in TSA agar, 
in order to remove attached phage particles and were used in further experiments. 
 
3.2.9. Fitness of phage resistant mutants 
The growth of the bacterial populations was quantified in the presence and in the absence 
of phage AS-D. This phage was selected for this experiments because was the most efficient 
phage to control A. salmonicida. Exponential host bacterial cultures of sensitive A. salmonicida 
strain (without phage contact) and resistant mutants of phage AS-D were adjusted to a 0.8 O.D. at 
600 nm (corresponding to a cell density of 109 CFU/mL). Fitness of each bacterial population was 
analyzed in two ways: (i) determining bacterial concentration (CFU/mL) after 6 and 12 h of 
incubation and (ii) determining population growth curve using the optical density (OD).  
Sensitive A. salmonicida was added to 2 of the 4 samples to obtain a final concentration of 
105 CFU/mL. One of the inoculated samples with sensitive A. salmonicida was inoculated with 
phage AS-D (sensitive with phage AS-D) to obtain a final concentration 107 PFU/mL and the 
remaining infected sample was not added of phages (sensitive bacteria without phage). Resistant 
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mutants to phage AS-D were added to 2 of 4 samples to obtain a final concentration of 105 
CFU/mL. One of these samples was inoculated with phage AS-D (resistant with phage AS-D) to 
obtain a final concentration 107 PFU/mL and the remaining infected samples were not added of 
phages (resistant bacteria without phage). Samples were incubated at 25 °C and bacterial 
concentration was determined in duplicate by the spread method in TSA medium, after an 
incubation period of 6 and 12 h post inoculation. The plates were incubated at 25 °C and bacterial 
concentration (CFU/mL) was calculated after 24 h incubation. Three independent experiments 
were performed for each condition.  
In parallel with this assay, we determined 12 h growth curves using a spectrophotometer 
(Halo DB- 20, Dynamica Scientific) using culture turbidity as a proxy for bacterial density. OD 600 
nm was taken at 0, 2, 4, 6, 8, 10 and 12 h post inoculation. Three independent experiments were 
performed for each condition. 
 
3.2.10. Assessment of the effect of physico-chemical factors in the phage survival 
The phage survival was determined, having into account the annual variations observed on 
Ria de Aveiro (Rebelo, 1992; Vargas, Vaz and Dias, 2017) for temperature, salinity, pH and 
irradiation (sunlight and UV-B light). Phage AS-D was selected for this experiment. The survival of 
ASD phage was tested in sterile synthetic seawater prepared by mixing Tropic Marin ProReef salt 
(Tropic Marine, Germany) with freshwater purified by a reverse osmosis unit, according to Silva et 
al. (2016). Thirty milliliters of water were filtered through 0.45 μm and then by 0.22 μm pore-size 
membranes (Poretics, USA), followed by the addition of phage suspensions at a final 
concentration of about 107 PFU/mL. In the experiments to evaluate the effect of pH, temperature 
and salinity, aliquots were collected after 0, 7, 14, 21, 49, 77, 107 days of incubation. To evaluate 
the effect of UV- B, the aliquots were collected after 0, 2, 4, 6, 8, 12 h of incubation. To assess the 
effect of solar radiation, the aliquots were collected after 0, 2, 4, 6, 8, 10 and 12 h. Phage titre was 
determined in duplicate through the double agar layer method and plates were incubated at 25 
°C for 18 h. Three independent experiments were performed for each condition. 
 
3.2.10.1. pH experiments 
In order to evaluate the effect of water pH, suspensions of phage ASD were added to sterile 
synthetic seawater with pH values of 5.5, 7 and 8. During these experiments, the temperature of 
the samples was kept at 25 °C and salinity at 35 g/L. 
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3.2.10.2. Temperature experiments 
To evaluate the effect of the temperature, the samples were kept at constant temperature 
(25, 37 °C and ambient temperature) in an incubator. The experiments were performed in sterile 
synthetic seawater at pH 7.0 and salinity at 35 g/L. 
 
3.2.10.3. Salinity experiments 
To assess the effect of the salinity, sterile synthetic seawater was prepared with a final 
salinity of 15, 20 and 35 g/L. During these experiments, the temperature of the samples was kept 
at 25 °C and the pH at 7.0. 
 
3.2.10.4. UVB experiments 
In order to evaluate the effect of the UVB (290–320 nm) it was used an ultra-violet type B 
lamp TL 20 W/12 RS (Philips, Holland) at a distance of 25 cm. The experiments were performed in 
sterile synthetic seawater at pH 7.0, salinity at 35 g/L and ambient temperature. 
 
3.2.10.5. Solar radiation experiments 
To evaluate the effect of solar radiation (200–1000 Wm2), suspensions of phage AS-D were 
added to sterile synthetic seawater with pH 7.0 and salinity at 35 g/L and exposed to natural solar 
radiation.  
 
3.2.11. Statistical analysis 
The statistical analysis of data was performed using the IBMSPSS Statistics 22.0 software. 
Kolmorov-Smirnov test was used to check for normal distributions and Levene test for 
homogeneity of variances. The significance of bacterial and viral concentrations between the 
treatments and during the experiments was tested using two-way ANOVA and Bonferrori post-
hoc test. For different treatments, the significance of differences was evaluated by comparing the 
result obtained in the test samples with the results obtained for the correspondent control 
samples, for the different times (Section 3.4). One way analysis of variance was used to analyze 
the statistical differences of the rates of phage-resistant mutants between single phage 
suspensions and phage cocktails (Section 3.7). Student's t-test was used to examine the 
differences between the concentration of resistant and sensitive bacteria in the presence of the 
phage after 6 and 12 h of incubation, and the differences between the growth of resistant and 
sensitive bacteria in absence of the phage after 6 and 12 h incubation (Section 3.3.8). Two-way 
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ANOVA with repeated measures was used to analyze the statistical differences between the 
growth curves of the sensitive and resistant bacteria in presence and absence of the phage during 
the sampling time (Section 3.3.8). The significance of the effect of physico-chemical factors on the 
AS-D phage and incubation time was assessed by one way analysis of variance (Section 3.3.10). A 
value of p < 0.05 was considered to be statistically significant. 
 
3.3. Results 
3.3.1. Phage isolation and enrichment 
Phages AS-D and AS-E show similarities to phage AS-A (Silva et al., 2016), forming clear 
plaques on the host strain with a diameter of 0.5–2mm (Figure 3.1). High titre suspensions (109 
PFU/mL) were obtained for the three phages. 
 
Figure 3.1: Phage plaque morphologies and electron micrographs of A. salmonicida phages. (A) Phage AS-D 
and (B) Phage AS-E. 
 
3.3.2. Virion morphology 
Based on the morphological analysis by TEM (Figure 3.1), all three phages were identified as 
order Caudovirales and family Myoviridae of double-stranded DNA phages (Figure 3.1). The 
phages have an elongated icosahedral head and a rigid tail with approximately 220 ± 5 nm long. 
 
3.3.3. Phage host range determination and efficiency of plating (EOP) analysis 
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Similarly to phage AS-A (Silva et al., 2016), AS-D and AS-E phages infect only its host without 
infecting Aeromonas sp. K15-2FS, A. salmonicida AH010906-3, A. salmonicida achromogenes, V. 
ordalii VI-30, Aeromonas caviae, A. hydrophila, V. parahaemolyticus, V. anguillarum, V. fischeri, P. 
damselae damselae, Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas putida, 
Pseudomonas gingeri, Pseudomonas segetis, two strains of S. enterica and eleven strains of E. coli 
(Table 3.1).  
 
Table 3.1: Host range and efficiency of plating of three A. salmonicida (CECT 894) phage isolates 
determined on 29 bacterial strains included in six genera. Clear lysis zone (+), no lysis zone (−). 
Species Infectivity of phage Efficacy of plating (%) 
AS-D AS-E AS-D AS-E 
A. salmonicida CECT 894 + + 100 100 
A. salmonicida AH010906–3 - - 0 0 
A. salmonicida  achromogenes 
AT4175 
- - 0 0 
Aeromonas sp. K15-2FS - - 0 0 
A. caviae - - 0 0 
A. hydrophilla ATCC 7966 - - 0 0 
V. parahaemolyticus DSM 27657 - - 0 0 
V. anguillarum DSM 21597 - - 0 0 
V. fischeri ATCC 49387 - - 0 0 
Vibrio ordalii VI-30 - - 0 0 
P. damselae damselae DSM 7482 - - 0 0 
P. aeruginosa - - 0 0 
P. fluorescens - - 0 0 
P. putida - - 0 0 
P. segetis - - 0 0 
P. gingeri - - 0 0 
S. Typhimurium ATCC 13311 - - 0 0 
S. Typhimurium ATCC 14028 - - 0 0 
E. coli ATCC 25922 - - 0 0 
E. coli ATCC 13706 - - 0 0 
E. coli B30 - - 0 0 
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E. coli AE11 - - 0 0 
E. coli AD6 - - 0 0 
E. coli AF15 - - 0 0 
E. coli AN19 - - 0 0 
E. coli AC5 - - 0 0 
E. coli Aj23 - - 0 0 
E. coli BN65 - - 0 0 
E. coli BM62 - - 0 0 
 
3.3.4. Burst size and explosion time 
Growth curves for phages AS-A, AS-D and AS-E were determined in TSB at 25 °C (Figure 3.2). 
From the triphasic curves obtained, an eclipse period of 20 min, a latent period of 30 min and a 
burst size of 22 ± 5 PFU/host cell were calculated for AS-A. The AS-D phage is characterized by an 
eclipse time of 30 min, a latent period of 40 min and each infected bacterium produced 5 ± 1 
PFU/host cell. AS-E is characterized by an eclipse period of 30 min, a short latency of 40 min and 
burst size of 10 ± 1 PFU/host cell. 
 
 
Figure 3.2: One-step growth curves of AS-A, AS-D and AS-E phages in the presence of A. salmonicida as 
host. Values represent the mean of three experiments; error bars represent the standard deviation.9 
 
3.3.5. Bacterial killing curves 
 
3.3.5.1. Bacterial killing curves using single-phage suspensions 
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The maximum of bacterium decrease with the AS-A, AS-D and AS-E phages was 4.0, 6.3 and 
6.1 log CFU/mL (ANOVA, p < 0.05) achieved after 8, 12 and 10 h, respectively, when compared 
with those of the bacterial control (BC) (Figure 3.3A). After 8 h of treatment, the rate of bacterial 
decrease with the phage AS-D was, in general, significantly higher (ANOVA, p < 0.05) than the one 
obtained with the phage AS-A. However, after 4 and 6 h of treatment, the bacterial reduction with 
phage AS-A was significantly higher (ANOVA, p < 0.05) than the obtained with the phages AS-D 
and AS-E (Figure 3.3A). After 12 h, the bacterial reduction was still considerably high (2.1, 6.3 and 
5.3 log CFU/ mL for phages AS-A, AS-D and AS-E ANOVA, p < 0.05) for three phages (Figure 3.3A). 
Bacterial density in the BC increased by 3.5 log CFU/mL (ANOVA, p < 0.05) during the 12 h 
of incubation (Figure 3.3A). The phage alone (PC) was constant during all of the time (ANOVA, p > 
0.05) and when the phages were incubated in the presence of its host a significant increase 
(ANOVA, p < 0.05) of 0.8, 1.7 and 1.7 log PFU/mL was observed for AS-A, AS-D and AS-E, 
respectively, after 4, 12 and 10 h of incubation (Figure 3.3B). 
 
 
Figure 3.3:  Reduction of A. salmonicida by the three phages (AS-A, AS-D and AS-E) at a MOI of 100 during 
12 h. A. Bacterial concentration: BC—bacteria control; BP—bacteria plus phage. B. Phage concentration: 
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PC—phage control; BP—bacteria plus phage. Values represent the mean of three experiments; error bars 
represent the standard deviation. 
 
3.3.5.2. Bacterial killing curves using phage cocktails 
The bacterial reduction was statistically different (ANOVA, p < 0.05) for the four phage 
cocktails (Figure 3.4A).  
The maximum of bacterium reduction with the AS-A/AS-D phage cocktail was already 5.4 
log CFU/mL (ANOVA, p < 0.05) after 10 h of incubation, being statistically different from the 
values obtained in the phage therapy with the single phage suspensions of AS-A and AS-D 
(ANOVA, p < 0.05) (Figure 3.4A). However, after 4, 6 and 8 h of incubation, the bacterial reduction 
with AS-A/AS-D phage cocktail was statistically different from that obtained with single phage 
suspensions of AS-D (ANOVA, p < 0.05) and similar to that obtained for the phage AS-A (ANOVA, p 
> 0.05) (Figure 3.4A).  
With the phage cocktail AS-A/AS-E, the maximum of bacterial decrease was 5.6 log CFU/mL 
(ANOVA, p < 0.05) after 10 h incubation. With the phage cocktail AS-A/AS-E, the maximum of 
bacterial reduction was 5.6 log CFU/mL (ANOVA, p < 0.05) after 10 h incubation. After 2 and 4 h of 
incubation, the decrease was significantly higher (2.7 and 3.6 log CFU/mL, respectively) from that 
obtained with the phage AS-A (0.9 and 2.1 log CFU/mL, respectively) and phage AS-E (0.7 and 0.8 
log CFU/mL, respectively) (ANOVA, p < 0.05) (0.7 and 0.8 log CFU/mL, respectively). However, 
after 8 h of incubation, the rate of bacterial decrease with phage AS-E was significantly higher (6.1 
log CFU/mL) from that obtained with the phage cocktail AS-A/ASE (5.6 log CFU/mL). 
In the phage therapy assays with the phage cocktail AS-D/AS- E, the maximum rate of 
bacterium reduction was 6.4 log CFU/mL after 12 h of incubation, which was significantly similar 
from that obtained with the phages AS-D and AS-E. The rates of bacterial reduction during the 
treatment, were statistically similar (ANOVA, p > 0.05) for the phage cocktail AS-D/AS-E and 
phages AS-D and AS-E (Figure 3.4A). 
When the assays of phage therapy were performed with the three phages altogether, AS-
A/AS-D/AS-E cocktail, the maximum rate of bacterial decrease was 5.7 log CFU/mL, achieved after 
10 h of incubation, being statistically different (ANOVA, p > 0.05) from the experiments with the 
phages AS-A and AS-D (Figure 3.4A). However, for the same period, no significant differences 
were observed in the therapy assays with the phage AS-E (ANOVA, p < 0.05). After 6 h of 
incubation, the rate of bacterial decrease with the phage cocktail AS-A/AS-D/AS-E was 3.4 log 
CFU/mL, which was not statistically different from the therapy with the phage AS-A (ANOVA, p > 
0.05), but was significantly different from the therapy with the other two phages alone (AS-D and 
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AS-E) (ANOVA, p > 0.05). However, after 8, 10 and 12 h of incubation, the bacterial reduction with 
the phage cocktail AS-A/AS-D/AS-E was similar to the one obtained with the phage AS-E (ANOVA, 
p > 0.05) (Figure 3.4A). Comparing the values of the BC during 12 h of the experiment, none 
significant differences were observed among the controls (ANOVA, p > 0.05) (Figure 3.4A). 
Bacterial density in the BC increased by 3.3 log CFU/mL (ANOVA, p < 0.05) during the 12 h 
of incubation (Figure 3.4A). Phage concentration was constant (ANOVA, p > 0.05) during the 12 h 
of experiment for the phage cocktail controls (PC) (Figure 3.4B). The suspensions with the phage 
cocktails, when incubated in the presence of the host, presented a significant increase (ANOVA, p 
< 0.05). An increase of 0.7, 0.9, 0.9 and 1.6 log PFU/mL was observed after 8 h of incubation 
(ANOVA, p < 0.05) for the phage cocktails AS-A/AS-D, AS-A/AS-E, AS-D/AS-E and AS-A/AS-D/AS-E, 
respectively (Figure 3.4B). 
 
 
Figure 3.4: Reduction of A. salmonicida by phage cocktails at a MOI of 100 during 12 h. (A) Bacterial 
concentration: BC—bacteria control; BP—bacteria plus phage. (B) Phage concentration: PC—phage control; 
BP—bacteria plus phage. AS-A - phage AS-A; AS-D - phage AS-D; AS-E – phage AS-E. Values represent the 
mean of three experiments; error bars represent the standard deviation. 
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3.3.6. Rate of emergence of phage-resistant mutants 
A. salmonicida showed different rates of phage-resistant mutants for single phage 
suspensions and for phage cocktails (Table 3.2), ANOVA, p < 0.05. Phage AS-D presented lower 
rates of phage - resistant mutants when compared with phage AS-A and AS-E (Table 3.2, ANOVA, 
p < 0.05). 
 
Table 3.2: Frequency of A. salmonicida spontaneous phage-resistant mutants for single phage suspensions 
(AS-A, AS-D, AS-E) and for phage cocktails (AS-A/AS-D, AS-A/AS-E, AS-D/AS-E and AS-A/AS-D/AS-E). 
 Control sample (CFU/mL) Sample treated with phages 
AS-A 1.75 ± 0.15×109 3.81 ± 0.18×105 
AS-D 1.68 ± 0.21×109 1.53 ± 0.24×105 
AS-E 1.82 ± 0.25×109 2.31 ± 0.23×105 
AS-A/AS-D 1.71 ± 0.23×109 2.80 ± 0.31×105 
AS-A/AS-E 1.63 ± 0.27×109 3.20 ± 0.29×105 
AS-D/AS-E 1.75 ± 0.21×109 1.83 ± 0.25×105 
AS-A/AS-D/AS-E 1.77 ± 0.23×109 3.01 ± 0.31×105 
 
3.3.7. Fitness of phage resistant mutants 
In the presence of AS-D, after 6 h incubation, no differences were found between the 
growth of resistant bacteria and the growth of sensitive bacteria (Figure 3.5, t=2.890, p=0.1018). 
However, after 12 h incubation was observed differences between the growth of resistant 
bacteria and the growth of sensitive bacteria (Figure 5, t=10.14, p=0.0096). Resistant bacteria 
reach a higher concentration at 6 and 12 h when compared to sensitive bacteria (Figure 3.5). In 
the absence of phage no differences were found between the concentration of resistant bacteria 
to the phage AS-D and the concentration of sensitive bacteria (Figure 3.5, t=0.4468, p=0.6987 at 6 
h and t=0.4167, p=0.7173 at 12 h). 
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Figure 3.5: Bacterial concentration of resistant mutants versus their sensitive bacteria in the presence (A) or 
absence (B) of phage AS-D after 6 and 12 h. 
 
In parallel with this assay, we determined the growth curves using the sensitive bacteria 
and resistant bacteria for the phage AS-D (Figure 3.6). Significant differences (ANOVA, p < 0.05) 
between the growth rate of the sensitive bacteria in presence the phage, and sensitive and 
resistant bacteria in absence of the phage and resistant bacteria with phage, after 8 h of 
incubation were detected. No difference in growth curves (ANOVA, p > 0.05) between the 
sensitive and resistant bacteria in the absence of phage and resistant bacteria with phage, during 
the 12 h of incubation, was observed. 
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Figure 3.6: Growth curves of sensitive bacteria and resistant mutants in presence or absence of phages 
during 12 h, with optical density readings at 600 nm. 
 
3.3.8. Assessment of the effect of environmental factors in the phage survival 
 
3.3.8.1. pH experiments 
When different pH values (5.5, 7 and 8) were tested, it was observed that the phage 
concentration slightly decreased with the increase of the pH; however, the differences among the 
three values of pH were not statistically significant (Figure 3.7, ANOVA, p > 0.05). In the three 
studied pH, phage AS-D persisted viable for at least 107 days at 25 °C (Figure 3.7). The abundance 
of phage AS-D remained constant during 49 days, then decreased about two orders of magnitude 
between 49 and 107th day (Figure 3.7, ANOVA, p < 0.05). 
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Figure 3.7: Survival of phage AS-D at different pH values. Values represent the mean of three experiments; 
error bars represent the standard deviation. 
 
3.3.8.2. Temperature experiments 
The reduction of the concentration of phage AS-D was higher at 37 °C than at 25 °C and 
ambient temperature (ANOVA, p < 0.05). A maximum decrease of 7 log PFU/mL was observed 
after 49 days when the samples were kept at a temperature of 37 °C, but after 21 days the 
decrease was of only 2 log PFU/mL. When the temperature was decreased to 25 °C, the rate of 
maximum reduction slightly increased to 2.0 log PFU/mL after 107 days of incubation, without any 
decrease after 21 days. The difference between these two temperatures was statistically 
significant (ANOVA, p < 0.05). At ambient temperature, the abundance of phage AS-D remained 
constant during 14 days (Figure 3.8, ANOVA, p > 0.05), then decreased about two orders of 
magnitude between day 14 and 107 (Figure 3.8, ANOVA, p < 0.05). 
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Figure 3.8: Survival of phage AS-D at different temperature values. Values represent the mean of three 
experiments; error bars represent the standard deviation. Amb: ambient temperature. 
 
3.3.8.3. Salinity experiments 
When different salinity concentrations (15, 20 and 30%) were tested, it was observed that 
the phage concentration decreased along incubation time, however, the differences among the 
three concentrations of salinity were not statistically significant (Figure 3.9, ANOVA, p > 0.05). For 
the three salinity concentrations, phage AS-D persisted viable for at least 107 days at 25 °C (Figure 
3.9). The abundance of phage AS-D decreased about three orders of magnitude after 107 days of 
incubation (Figure 3.9, ANOVA, p < 0.05).  
 
 
Figure 3.9: Survival of phage AS-D at different salinity concentrations. Values represent the mean of three 
experiments; error bars represent the standard deviation. 
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3.3.8.4. UVB experiments 
When the phage AS-D was exposed to UV-B irradiation, it was observed that the phage 
concentration decreased during 12 h of incubation (Figure 3.10). The abundance of phage AS-D 
exposed to UV-B irradiation was similar to the control during first 8 h of incubation (Figure 3.10, 
ANOVA, p > 0.05), then decreased about 1.3 log PFU/mL between 10 and 12 h (Figure 3.10, 
ANOVA, p < 0.05). 
 
 
Figure 3.10: Effect of UV-B irradiation on the phage AS-D during 12 h. Values represent the mean of three 
experiments; error bars represent the standard deviation. UVB: UV-B irradiation. 
 
3.3.8.5. Solar radiation experiments 
When the phage AS-D was exposed to solar radiation, it was observed that the phage 
concentration decreased during 12 h of incubation (Figure 3.11, ANOVA, p < 0.05). After 12 h of 
incubation, the abundance of phage AS-D decreased 2.7 log PFU/mL when compared with control 
(C AS-D) (Figure 3.11, ANOVA, p < 0.05). 
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Figure 3.11: Effect of solar radiation on the phage AS-D during 12 h. Values represent the mean of three 
experiments; error bars represent the standard deviation. SR: solar radiation. 
 
3.4. Discussion 
There are few studies about the use of phages to control furunculosis in aquaculture. In a 
previous work of our group, phage AS-A successfully controlled A. salmonicida in juvenile fish 
(Silva et al., 2016), however, some bacteria developed resistance. As it has been reported that the 
development of phage-resistance can be circumvented by the use of phage cocktails (Crothers-
Stomps et al., 2010; Filippov et al., 2011; Chan, Abedon and Loc-Carrillo, 2013), we isolated two 
more phages that were used together with phage AS-A as cocktail in order to control phage-
resistance emergence. In fact, the results of this study showed that, in general, phage cocktails 
were more effective to control the bacterium. The bacterial reduction with the cocktails was 
higher, namely when phage AS-A was combined with one of the two new phages or with both, 
but the main difference in the bacterial decrease was found in the treatment time. When the 
phage cocktails were used, the maximum of bacterial reduction was observed after 4–6 h, but 
with the single suspensions the maximum decrease was observed after 8–10 h of treatment. The 
two new phages, although needing a long period to control A. salmonicida than the phage AS-A, 
reduced the bacterial concentration more effectively. This can explain the fact that cocktail 
including phage AS-A and one of the new ones was more effective to control the agent of the 
furunculosis than the other phage combinations. Additionally, when the cocktails were used, in 
general, the number of bacteria that regrowth was lower than that observed when the phages 
were tested as single phage suspensions. These results are in accordance with other studies 
(Wagner and Waldor, 2002; O’Flynn et al., 2006; Mateus et al., 2014) that achieved a faster and 
higher bacterial decrease by using phage cocktails, than that obtained with single phage 
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suspensions. However, the use of phage cocktails, as well as the use of single-phage suspensions, 
did not prevent the occurrence of phage-resistant mutants. Nonetheless the frequency of phage-
resistant mutations was low, 10−4–10−5 CFU/mL, and was slightly lower for phage cocktails than 
for single phage suspensions, as it was observed in other studies (Pereira et al., 2016a, 2017b). 
With such a small mutation frequency, phage resistance should not hinder the use of phages as 
biocontrol agents against pathogenic bacteria, as stated before by other authors (Flynn et al., 
2004; Tanji et al., 2004). It has been suggested by other authors that phage exposure could be 
fitness cost for bacteria (Bohannan et al., 1999; Brockhurst et al., 2005), which can contribute to 
their elimination from the environment faster than their wild-type parents. However, this 
hypothesis can vary across environment and degree of competition for resources (Lennon et al., 
2007; Quance and Travisano, 2009). In this study, the experiments of fitness of phage resistant 
mutants, showed no differences between the concentration of sensitive bacteria and resistant 
mutants when grown in the absence of phage AS-D. However, these experiments were done in 
nutrient rich medium (culture medium) without the presence of competition. Similar results have 
been observed for Pseudomonas syringae (Meaden et al., 2015) and Escherichia coli (Pereira et 
al., 2017b). Further studies are necessary to evaluates the cost of resistance in natural 
aquaculture systems.  
As phage resistance may result mainly from mutations that alter cell surface receptors, 
restriction modification, or abortive infection associated with the presence of clustered regularly 
interspaced short palindromic repeats (CRISPRs) in the bacterial genome (Allison and 
Klaenhammer, 1998; Barrangou et al., 2007) therefore, when combining phages it is important to 
select different ones. The three phages presented similar morphology, however, evident 
differences between them, namely in their burst size, explosion time and bacterial kill curves, 
were observed. The growth characteristics of phage AS-A were clearly different from those of 
phages AS-D and AS-E. Phage AS-A presented the highest burst size (22 ± 5 PFU/host cell) around 
4 and 2 times higher than that of phage AS-D (5 ± 1 PFU/host cell) and AS-E (10 ± 1 PFU/host cell), 
respectively, and the shortest latent period, 30 min (40 min for the phages AS-D and AS-E). 
Consequently, the bacterial reduction by phage AS-A starts sooner than that when the other two 
phages were tested. However, phages AS-D and AS-E caused a higher reduction of A. salmonicida 
(maximum reduction of around 6 log CFU/mL) than phage AS-A (maximum reduction of around 4 
log CFU/ mL). This can explain the more effective bacterial control when phage AS-A was 
combined with phage AS-D or phage AS-E. However, no significant difference in the rate of 
emergence of phage-resistant mutants was observed when these two phage combinations were 
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tested. Further evaluation trials must still be performed (e.g., whole genome sequencing) to 
identify the presence of any genes encoding toxins and/or antibiotic resistance. 
Considering that in outdoor facilities aquaculture water is exposed to natural variation in 
physical and chemical parameters, thorough investigations addressing different field conditions 
are required for the design and implementation of effective phage therapy protocols. This 
becomes particularly important when phage therapy is applied to semi-intensive marine earth 
ponds in temperate climates, a culture technique widely employed throughout the world, 
because in these systems, environmental parameters can shift significantly through the year. 
One important factor that influences phage stability is the acidity of the environment 
(Jończyk et al., 2011). The pH has been shown to be an important control factor, influencing 
attachment, infectivity, intracellular replication and multiplication of phages (Pirisi, 2000; 
Leverentz et al., 2001, 2004). Generally, pH values < 5 and over 10 have shown to be less efficient 
in studies on the lytic activity of phages, being the optimum conditions around a neutral pH of 6–8 
[31, 48, 79]. Unfavorable pH can interfere with the lysozyme enzyme and/or with other capsids 
proteins, thus preventing phage attachment to receptor sites on the host cell (Leverentz et al., 
2001, 2004). In this study, pH values ranging from 5.5 to 8 were tested, which are included within 
the optimum neutral range of pH values, and survival of the phages was not significantly affected. 
This means that the seasonal variation of pH in aquaculture water would not affect the efficacy of 
phage therapy. 
Temperature is also a crucial factor for bacteriophage survivability (Nasser and Oman, 
1999; Olson et al., 2004). It plays a fundamental role in attachment, penetration and 
multiplication (Jończyk et al., 2011). At low temperatures, fewer phage genetic material enter into 
bacterial host cells; therefore, fewer of them can be involved in the multiplication phase. High 
temperatures can extend the length of the latent stage (Tey et al., 2009). In this study, the 
decrease in concentration of phage AS-D was significantly higher at 37° than at 25 °C and ambient 
temperature. However, as in aquaculture water this high temperature is not reached, 
temperature would not be a problem to apply phage therapy in the aquatic environment. 
Phages require salts at low concentrations to be successful during the infection process and 
growth (Baross et al., 1978). At low concentrations, salt ions interact with proteins and stabilize 
protein structure by neutralizing protein charges. However, at higher concentrations, NaCl 
increases the thermal denaturation of the proteins and can also adversely affect the structural 
stability of the phage nucleic acid (Fennema, 1996). In this study, salinity concentrations ranging 
from 15 to 35% were tested and phage AS-D survival was not significantly affected. Similar results 
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were also obtained for other phages (Wu and Chao, 1987). This means that phage AS-D can be 
used to control furunculosis in marine and freshwater fish (the phage AS-D as well as the other 
two phages are stable in buffer for more than one year). 
Solar radiation or, more specifically, UV radiation (UV) has been recognized as the most 
important factor in the loss of phage infectivity in surface coastal water. UV radiation destroys 
viruses by chemically modifying their genetic material, DNA and RNA. In fact, the abundance of 
phage AS-D was decreased when exposed to solar radiation (decreased 2.7 log PFU/mL) and UV-B 
radiation (decreased 1.3 PFU/mL). Suttle and its coworkers observed that sunlight is the dominant 
factor implicated in the loss of infectivity in seawater viruses (Suttle and Chen, 1992; Suttle and 
Chan, 1994). A way to overcome this problem would be to apply phage therapy at the end of the 
day or during night period, in which UV radiation is limited. 
Overall, phage AS-D was affected by the variation of the physicochemical factors, namely by 
solar radiation and temperature, this can be overcome by the application of phage at the end of 
the day or at night. Although water temperature in outdoor aquaculture facilities does not reach 
37 °C, applying the phages at the end of the day or during night period, the temperature can also 
be more easily controlled, allowing phage therapy to achieve better results. Taking into account 
the results of this study and the fact that the variation of pH and salinity in aquaculture waters is 
moderate (Pereira et al., 2011b), these parameters should not affect phage survival in field 
conditions. 
In future near, it will be essential to understand the efficiency of these single phage 
suspensions and cocktails in the field, in aquaculture systems. In fact, one of the current 
challenges faced when performing phage biocontrol studies is to demonstrate their feasibility in 
vivo. According to several authors, the in vitro experiments are not sufficient to understand 
phage–bacteria interactions in vivo (Silva et al., 2014a; Pereira et al., 2016c, 2017b; Silva et al., 
2016). Numerous other factors, beside the physical and chemical characteristics tested in this 
study, can affect the survival and lytic properties of the phages in aquaculture systems, e.g., 
delivery mechanism, fish immune response, presence of zooplankton, phytoplankton and 
bacterioplankton (Jończyk et al., 2011; Maura and Debarbieux, 2011; Madsen et al., 2013; Ly-
Chatain, 2014; Sabouri et al., 2017). In future, it will be essential understand how the interaction 
of these factors influences the efficiency of phage therapy in aquaculture tanks. Application of 
phages to control fish pathogens in aquaculture requires also detailed insight to the efficiency of 
dispersal and persistence of infective phages in the target organs, as well as the factors that 
regulates their infectivity in fish. 
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3.5 Conclusions 
The results of the present work suggest that phage therapy using phages combined in 
cocktails or even single phage suspensions can be an effective alternative to control the agent of 
the furunculosis. In outdoor aquaculture facilities, phages should be applied at the end of the day 
or during night period in order to have a higher bacterial control. Nonetheless, further studies are 
needed, namely those performed in aquaculture systems, to understand the true potential of 
these three phages to control A. salmonicida. 
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